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ABSTRACT 
 
 
 The widespread availability of antimicrobial chemotherapeutics over the last half 
of the twentieth century has offered dramatic increases in life expectancy. Unfortunately, 
many pathogenic agents are exhibiting ever increasing resistance to many frontline 
antibiotics.  New chemotherapeutic agents are urgently needed to combat this threat; this 
work seeks to illustrate applications in which mass spectrometric techniques may be 
applied to the investigation of novel, small molecule chemotherapeutics for the treatment 
of bacterial infections. Chapter 1 contains an introduction to mass spectrometry, as well 
as an overview of relevant chromatographic techniques. Chapter 2 introduces the 
bacterium F tularensis and M ulcerans and details the MS based investigation of their 
secreted virulence factors. Chapter 3 introduces a human pathogen of particular concern, 
M tuberculosis, and contains a detailed reporting on the MS based investigation of 
internally synthesized compounds for the treatment of latent Tb.  
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PREFACE 
 
 
 I have always had an interest in the electromechanical aspects of technology.  I 
remember in the 5th grade my father returned from work with a large box containing the 
remains of a number of derelict computers. These 8086’s were obsolete even by 1991 
standards but my dad simply said, “I thought you might have fun playing with these” and 
handed me the box with a smile. It took me a few weeks but soon enough I sat in front of 
the monochrome amber glow of a fully functional computer.  Since that day I have had a 
profound interest in electronics. I have assembled numerous computers since but none 
have elicited such fond memories as playing Zaxxon on what entered my possession as a 
box bound for the dumpster. 
 
 In a freshman general chemistry class I was introduced to concept mass 
spectrometry (MS). MS would soon serve to combine my lifelong interest in computers 
and electronics to my new love of chemistry. Upon receiving my undergraduate in 
chemistry I continued to develop my interest in mass spectrometer entering Dr. Richard E 
Lee’s laboratory in pursuit of a PhD in Bioanalytical Chemistry from the University of 
Tennessee College of Graduate Health Sciences of which this work serves as the 
conclusion. 
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CHAPTER 1.    INTRODUCTION TO MASS SPECTROMETERY 
 
 
The Early History of Mass Spectrometry 
 
 In most scientific programs mass spectrometry (MS) falls largely under the guise 
of analytical chemistry.1 However the early history of MS is predominately the story of 
physics,2 more precisely the story of the electron.3 By the late 1860’s physicists had 
become increasingly interested in a strange phenomenon by which fluorescence could be 
observed around the cathode of electrochemical reaction vessels.4 While many in the 
physics community were investigating the nature of cathode rays, there still existed great 
uncertainty as to their physical composition.5   
 
 Early in his career, J.J Thomson, worked to investigate the laws which governed 
the transmission of electricity through gas and became interested in the propagation and 
composition of cathode rays.6 Convinced the observed fluorescence must be attributable 
to the interaction of an invisible force with the glass container,7 Thomson set out to 
design an apparatus capable of measuring this unknown force.8 This instrument, the first 
mass spectrometer, was used to measure the mass-to-charge ratio (m/z) of hydrogen gas 
as early as 1899.9 
 
 Thomson continued to improve his spectrometer leading him to the discovery of 
the electron, the elementary particle responsible for the propagation of cathode rays, for 
which he would receive the Nobel Prize in Physics in 1906.10 Thomson, assisted by 
Francis Aston, continued to study the ability of magnetic and electric fields to influence 
the propagation of positive ions formed by electric discharge.11 This work led to the 
generation of the first molecular mass spectra by positive ray spectrograph.12 While 
Aston and his colleagues used the new instruments to investigate chemical entities, they 
were primarily concerned with developing MS as to tool to tease out the physical 
composition of the atom.13 
 
While the early years of MS were concerned with answering larger, theoretical 
questions, the dawn of World War II united many early MS pioneers together under one 
banner.2, 14 Could MS prove to be a viable method by which to isolate the gaseous 
isotopes of uranium? In 1939, Albert Nier effectively answered this question by 
accumulating nanogram quantities of 252Pu using a magnetic sector MS of his own design 
located at the University of Minnesota.15 Using this data, calutrons were constructed at 
what is today Oak Ridge National Laboratories, to perform the bomb scale separation of 
235U from its parent 238U.   
 
Magnetic sectors are based upon the realization that electric and magnetic fields 
may be used to influence the trajectory of a charged gaseous (ionic) species in a sufficient 
vacuum as to avoid kinetic interactions (collisions).16 While Thompson’s MS employed 
high voltages to manipulate ions, the decoupling of the electrical and magnetic 
components proved instrumental in the design of practical spectrometers.17 While the 
physics of MS remains unchanged from Thompson’s first prototypes (the lighter the 
 2 
molecule, the greater the deflection) sectors were the first to influence ion trajectory 
based upon the duality inherent to the Lorentz Force Law.18  
 
 
Equation 1     Lorentz Force Law 
 
)( BvEQF ×+=  
 
By definition; a Lorentz force is point charge due to the perturbation of an 
electromagnetic field.(Whereas F is the force applied to the ion, Q is the charge expressed 
by a particle, E denotes the contribution of an electric field, B the contribution of the 
magnetic field and v represents velocity) 
 
 
Equation 2     Electric Component of Lorentz Force (Electric Sector)  
 
qEF =  
 
One of Thompson’s greatest contributions to the advancement of magnetic sector 
instruments was his realization electric and magnetic fields may be used to differentially 
influence the trajectory of an ion (the principal concept on which the QMA was later 
built). (F again represents force, lower case q represents a component of the particle 
charge Q, while E denotes the electric field.) 
 
 
Equation 3     Magnetic Component of Lorentz Force (Magnetic Sector)  
 
qvBF =  
 
F again represents force, lower case q represents a component of the particle 
charge Q, while v denotes velocity and B the magnetic field.  
 
Equation 4     Newton’s Second Law  
 
ma
dt
dvmF ==  
 
As even the most rapidly traveling ions in a mass spectrometer fail to even 
encroach upon relativistic velocities, the second law may be expressed quite simply. 
(Whereas F is again representative of applied force, m denotes the mass of the ion and 
represents acceleration.)   
 3 
Equation 5     Classic Motion of Charged Particles 
 
BvEaQm ×+=)/(  
 
The substitution of Equation 1 functionalized for net charge.   
 
 
Equation 6     Substitution of Q 
 
eQz /=  
 
As written. this equation technically equates mass number to the number of 
elementary charges (e) in the case of mass spectrometry;, the localization of charge is 
often considered to be inconsequential, allowing for the direct substitution of the formally 
unconstrained charge number (z). 
 
 
Equation 7     Motion of Charged Particles 
 
BvEazm ×+=)/(  
 
By war’s end, multiple discrete sectors had been assembled into hyphenated 
spectrometers.19 Composite sector MS proved a significant advance in resolution as ions 
of interest could be preselected in the first field,20 then further resolved using subsequent 
sectors. In this way composite sectors were able to offer the performance of more modern 
spectrometers before the technology existed to operate quadrupoles.21  
 
  
Mass Spectrometry as a Tool for Chemical Investigation  
 
The mid 1940’s saw the first commercialization of magnetic sector based 
instruments.22 These early commercial sectors differed from the pioneering designs of 
Neir in their use of electron ionization.23 While previous MS relied predominately upon 
an arc discharge for the generation of ions, commercial instruments relied upon the more 
robust electron ionization sources.24 Electron ionization (EI) mass spectra were found to 
be informatically superior to those of arc discharge (AD).25 The highly uniform nature of 
EI allowed for the formation of the first MS spectral libraries.26   
  
 4 
Equation 8     Representation of Gas Phase Electron Ionization 
 
−•+− +→+ eMeM 2  
 
In this representation, M denotes the molecular analyte, e- the accelerated electron 
and M+ the newly ionized analyte. 
 
While advances in EI gaseous ion spectrometry continued throughout the late 
1940’s, the incompatibility of MS with liquid analyses limited the widespread adoption 
of the technique.27 In many ways the advancement of MS stalled, as other analytical 
techniques were considered less troublesome.28 It required the commercial introduction 
of gas chromatography in the early 1950’s to renew interest in MS as a chromatographic 
detector29. Though initially problematic, the interface of gas chromatography and mass 
spectrometry proved to be ideal.30 A sample could be prepared in a volatile solvent and 
injected into the GC, which desolvated the analyte and delivered it to the MS in a gaseous 
form. While GC had limitations (sample volatility), EI-GC/MS served to renew interest 
in MS development.31 As GC continued to develop, the need for faster, lower cost 
spectrometers became apparent.32  
 
 
Equation 9     Potential Energy of an Ion in an Electric Field 
 
qUEP =  
 
In this equation Ep represents potential energy, q the fractional charge of the 
particle and U denotes voltage (difference in potential between anode and cathode) 
 
 
Equation 10       Kinetic Energy of an Ion in an Electric Field 
 
2
2
1 mvEk =  
 
From Equation 9, if a charged particle at rest encounters voltage (U)(as is the case 
in a time-of-flight mass spectrometer) the potential energy of the particle will be 
completely converted to kinetic energy (Equation 10) Whereas Ek represents the kinetic 
energy of an ion, m denotes mass and v represents velocity. 
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Equation 11       Ionic Energy as a Function of Time 
 
𝐸𝑝 = 𝐸𝑘 = 12𝑚�𝑑𝑡�2 = 𝑞𝑈 
 
In the TOF-MS the potential energy of an ion is converted to kinetic energy 
making Ep and Ek effectively equal. In a TOF the ion will experience an intense moment 
of acceleration, and then its resultant velocity will remain unchanged for the remainder of 
its flight down the RF free section of the flight tube. In this way the velocity of a ion as it 
travels through the flight tube may be determined as the path length (distance, d) and the 
time of flight, t, may be easily measured. 
 
 
Equation 12       Ionic Energy as Expressed by Flight Time 
 
𝑡 =  𝑑
√2𝑈  �𝑚𝑞 = 𝑘�𝑚𝑞  
 
Essentially a rearrangement of Equation 11 expressed as an extrinsic function of 
flight time. As distance (d) and potential (U) are functions of instrument design they may 
be considered as constants and directly substituted for (k) as it denotes proportionality.  
 
 
Equation 13      Generic Time-of-Flight Equation 
 
𝑡 = 𝑘�𝑚
𝑧
 
 
As in previous examples the empiric charge state (q) may be directly subsisted for 
the less constrained z, yielding this familiar expression.  
 
Throughout the early 1950’s the speed of single scanning sectors greatly limited 
their ability to interface with GC,33 while the expense associated with most composite 
sectors remained prohibitively high.34 A number of the new time-of-flight (TOF) 
spectrometers were constructed and reported by 1956.35 The goal of the early TOF 
designers was to create an instrument with the performance characteristics of a composite 
sector but with a higher scanning speed and at a lower cost.36 The theory governing the 
operation of a TOF is quite similar to that of a sector, though it relies on time not force to 
afford separation.37 The key to the TOF’s speed and cost savings was its amazing 
simplicity. Early TOF mass analyzers consisted of only a small accelerator, a length of 
evacuated tubing terminating in a faraday cup, itself connected to an oscilloscope.38    
 
In a TOF mass spectrometer all incoming ions are accelerated by a known electric 
field, converting the ions potential energy to kinetic energy.39 These energized ions fly 
into a field–free drift tube under high vacuum where separation occurs based upon a 
particles velocity. In this way a particles velocity may be very accurately measured based 
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upon the time required to complete the “flight” to the detector.40 The function of a TOF is 
in many ways analogous to a very accurate clock. The TOFs robustness, GC 
compatibility41 and relatively low operating cost (sectors consume a great deal of 
electricity) coupled with the development of a compatible fast atom bombardment 
ionization source42 secured the TOF-MS tenure in many analytical laboratories. 
 
During the mid-1970’s and early 1980’s a number significant advances served to 
again rejuvenate MS as GC had done 2 decades prior: the commercialization and 
widespread adoption of reverse-phase high pressure liquid chromatography43 (HPLC), the 
development of electrospray ionization (ESI)44 by John Fenn and the widespread 
availability of computerized electronics facilitating the miniaturization of quadrupoles.45 
As with GC before it, the coupling of LC to MS initially proved difficult, as the high 
vacuums necessary for MS were physically incompatible with the LC’s liquid elutant. In 
1989 John Fenn described the construction of an ESI source for the “mass spectrometry 
of large biomolecules.”46   
 
Analytes dissolved into a volatile organic solvent were introduced by a low 
pressure pump to Fenn’s ESI source.47 The analyte was then dispersed into a fine spray 
upon exit of the electrified capillary. The “electrospray” would then be subjected to 
continued desolvation. As the size of the droplets continues to decrease the density of 
their electric field intensifies.48 Like charges began to repel one another, greatly 
increasing the surface tension of the particle. At some point (Rayleigh limit), the particle 
can no longer tolerate this increase in tension and dissociates in smaller droplets of 
discrete positive and negative charge. This cycle of evaporation, charge increase, 
repulsion and (Coulombic) explosion continues until only carrier-free molecular ions 
remain.49 
 
ESI provided a means to rapidly desolvate the LC elutant, and avoided damage to 
the vacuum system of the MS. While GC/MS precluded the investigation of most non-
volatile analytes, many common pharmaceutical and industrial materials were found to be 
compatible with LC/ESI-MS based analysis.50 Though the Fenn source was constructed 
for the investigation of macromolecules, lessons gleaned through its design and operation 
were quickly applied on a commercial scale to the investigation of large and small 
molecules alike.51  
 
 The early 1980’s also witnessed the commercialization of spectrometers based 
upon Wolfgang Paul’s Quadrupole Ion Trap52 (QIT) as well as the widespread 
availability of MS systems based upon the relatively low cost quadrupole mass 
analyzer53(QMA). While QMA based instruments are generally referred to as mass 
spectrometers, their function is more analogous to that of a mass filter than of a 
conventional MS.54 In the QMA, ions within a relatively narrow mass window (+/- 1 
amu) are allowed to pass through the quadrupole while ions outside the window are 
effectively filtered out. In this way a QMA emulates the function of a true mass 
spectrometer by rapidly sweeping its’ small bandpass region across a broader scale.55  
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In addition to its relatively low cost, QMAs offer a number of advantages over 
traditional sectors and TOFs in applications where high mass accuracy is unnecessary. 
The small size of the QMA allows for the ion source and detector to remain in close 
proximity (as little as 12 cm) while the strong “saddle field” effects allow the analyzer to 
operate at vacuum levels more easily achievable in the common laboratory56 (3 x 10-5 
Torr). The typical QMA consist of four circular electrodes positioned in a radial array, at 
a distance proportional to their hyperbolic cross section (Equation 14). The QMA is then 
utilized through the application of alternating time dependant direct current (DC) and 
time-independent alternating current (AC) electric potentials.57   
 
 
Equation 14      Approximation of Ideal Quadrupole Field Radius 
 
𝑟 = 1.148 𝑟0 
 
While no man-made hyperbolic field may be considered ideal, over forty-five 
years of instrument design have suggested Equation 14 as the most appropriate geometry 
for the construction of a quadrupole hyperbolic array. Whereas r represents the radius of 
the electrodes and ro the effective quadrupole field radius   
 
   The rapidly alternating electric potentials localized around the hyperbolic 
electrodes serve to influence the flight of ionic species introduced into the QMA.* While 
the electrical gradients refresh at a very high frequency (>2kHz), an effort can be made to 
visualize a single electronic rotation responsible for the eventual generation of the 
QMA’s saddle field.58 It is common practice to describe ionic trajectories in terms of 
vectors, by convention X and Y describe the ions location relative to the cross-section of 
the electrode array while Z represents the distance the ion has traveled down the length of 
the analyzer. To aid in the conceptualization of this electromagnetic phenomenon the X-
Y and X-Z influences will be considered separately, also, an attempt will be made to 
separate the time-dependant (alternating) and time-independent (direct) electronic 
influences into their principal components.   
 
When an AC voltage is applied to an electrode pair, in the case the potential will 
be applied to the X electrodes thereby influencing the trajectories of ions in an X-Z 
orientation, each X electrode will spend half of the cycle positively charged while the 
opposite electrode conveys a negative potential.59 In a conventional quadrupole, each of 
the two electrode pairs (X &Y) remain 180o out of phase at all times, in this way when a 
positive potential is conferred to one electrode, an identical negative charge is conferred 
 
______ 
*While an effort has been made to introduce the mathematical basis of instruments until 
this point, it would not be reasonable to introduce the advanced differential equations 
governing the operation of the QMA given the already considerable length of this 
chapter. For the concerned reader a number of articles are readily available which discuss 
the quantum-mechanical principles of the quadrupole array in depth, including an 
excellent piece by Philip Miller at the University of Arizona.60 
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to the electrode spatially opposite. Should positively charged ions be introduced during 
this electronic cycle, again only considering travel in the X-Z plane relative to the center 
axis of the array, positively charged ions experiencing a net positive AC potential will be 
repelled (focused) towards the center of the quadrupole.61 
 
As the array exists in phased equilibrium, the inverse is also true, when a negative 
potential is expressed the positive ions will be attracted towards the negatively charged 
poles, effectively defocusing the ion beam.62 Should the defocusing interval be sufficient 
in duration, the positively charged ions will eventually collide with the negatively 
charged electrode and be excluded from the ion beam.63 In this way the ionic trajectories 
through a QMA may be influenced both by the perturbation of the electronic potentials 
expressed by the electrodes and by the duration of those potentials.  
 
 The Y-plane, time independent DC electrodes serve to compliment the focusing 
action of the X-plane to perturb the flight of ions in a mass dependent fashion.64 When 
the alternating and direct potentials are evaluated in concert with time, the mass focusing 
properties of the QMA began to become evident. Should an amalgam of ions be 
introduced into the array, the light and heavy species would interact with the electronic 
gradients quite differently. If an ion is quite heavy, its resultant momentum (trajectory) 
will be largely unaffected by rapid perturbations of the electronic gradient and the ion 
will only feel the net effect of the electric potential.   
 
Due to the conservation of momentum, heavy ions tend only to be effected by 
time independent forces.65 Conversely, very light ions will be significantly perturbed by 
very rapid (time-dependent) oscillation of the electric gradient in the array. In fact, small 
ions may be accelerated rapidly enough to exit the ion beam entirely and collide with the 
oppositely charged electrode, thus being effectively mitigated from detection. In this way 
a QMA is capable of excluding ions above or below a critical value based upon the speed 
at which an ion can respond to the defocusing potential exerted upon it.66 The undesirable 
ions are allowed to collide with the electrodes and be excluded from the ion beam while 
ions of a desired mass are allowed to traverse the array and be counted by the detector.67  
 
 Many modern analytical laboratories now rely on the implementation of 
hyphenated or hybrid mass spectrometers.68 In this way, scientists are able to overcome 
many of the physical limitations inherent to a single spectrometer type. While in no way a 
modern implementation, the quadrupole-TOF remains the centerpiece of many small 
molecule and proteomic laboratories alike and is responsible for a great deal of the data 
outlined in this work. 
 
 
Introduction to Chromatography 
 
 The term “Chromatography” has come to be synonymous with numerous 
laboratory techniques employed in the separation of mixtures.69 In the most generic of 
terms, the analyte of interest is introduced into a liquid (LC) or gas (GC) mobile phase 
which serves to transport the sample through a structurally constrained stationary phase.  
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The analyte is then separated into its principal components as some compounds are 
capable of migrating through the stationary chemistry more rapidly than others.70  The 
speed at which an analyte achieves equilibrium between chromatographic phases and is 
ultimately eluted from the chromatographic column (retention time) is largely a function 
of a compounds physical-chemical properties, which in the case of separation sciences, is 
often expressed as a partition coefficient.71 
 
 
Gas Chromatography 
 
 A typical gas chromatograph consists of a carrier gas source, a sample injector, a 
column (contained in an oven) and some means of detection.72 While derivatization 
techniques exist, analytes are generally considered to be GC compatible if they possess a 
relatively low boiling point (<250oC) and they do not tend to undergo thermal 
decomposition (non-thermolabile).73 In GC the analyte is dissolved into a low-boiling 
solvent (such as CH3OH) and is introduced to a heated injector. Upon injection the 
solvent is immediately evaporated yielding an injection chamber filled with nebulized 
analyte and residual injection solvent.74 A carrier gas (mobile phase) then transports the 
vaporized analyte/solvent matrix into the chromatographic column housed in a high 
temperature oven.  The column serves to structurally support the chromatographic 
stationary phase to which the analyte/solvent matrix is introduced at the column head.75 
Two types of oven programs are often used to achieve analytical separation; isothermal 
and thermal gradient. In an isothermal program the oven (and the column it contains) are 
preheated to a temperature at which the analyte of interest will be retained (equilibrate 
with the stationary phase) while the solvent matrix will be virtually unretained and eluted 
rapidly.76 
 
In the case of a thermal gradient, the oven is set to a sufficiently low temperature 
to allow the analyte/solvent matrix to initially equilibrate with the stationary phase.  The 
oven is the heated in a controlled fashion with the solvent eluting first followed by the 
analytes of interest, the use of a thermal gradient often aids in the mitigation of solvent 
diffusion effects often seen in isothermal runs however at the cost of increased 
complexity.77 As the analytes are eluted from the column, the elutant is directed to some 
form of detector.   
 
The fifty plus year history of GC has seen numerous detection methodologies, 
though today most pharmaceutical laboratories often rely primarily on a combination of 
three,78 Flame Ionization Detector (FID), Electron Capture Detector (ECD) and MS.  As 
MS is the focus of the work only FID and ECD will be discussed briefly here.   
 
 
Flame Ionization Detector 
 
Today FID has established itself as a popular and robust detection method; it 
relies upon the ability of a hydrogen/oxygen (air) flame to ionize organic molecules. 
These ions are then directed across an adjacent electrode, the resultant ion current is 
 10 
directly proportional to the ions generated per unit time.79 The FID has a number of 
endearing qualities; very low cost, minimal maintenance, no radionuclide, exceptional 
linearity and dynamic range and a very reasonable sensitivity for carbon containing 
compounds.80 For these reasons the FID has established itself as a near universal GC 
detector, with many laboratories still relying on it heavily to this day.81 
 
 
Electron Capture Detector  
 
While much less common than the FID, the ECD enjoyed a significant success 
throughout the history of GC.82 The ECD relies on the use of a β radiation source (63Ni) 
and offers exceptional sensitivity in the detection of halogenated compounds.83 In an 
ECD β particles are emitted into a makeup chamber filled with a continuous supply of 
nitrogen.84 The low excitation energy of nitrogen allows the β particle to easily strip a 
valence electron; these electrons collide with additional nitrogen atoms stripping 
additional electrons resulting in a β particle induced electron cascade. These many 
electrons are then attracted towards a positively charged anode generating an electric 
potential. As the elutant is introduced into the detector, the analyte effectively disrupts 
the flow of electrons and reduces the electric potential between the ECD’s cathode and 
anode. This loss of voltage is proportional to the concentration of analyte in the detection 
chamber at any given time. The ECD has been relied upon heavily in the past for the 
detection of nitro, nitrile and halogenated compounds. While the ECD will likely remain 
significantly utilized for the foreseeable future, regulatory difficulties arising from the 
ECD’s reliance of radionuclides have led many laboratories to transition from ECD to 
MS based instrumentation.85 
 
 
Liquid Chromatography 
 
The term “liquid chromatography” (LC) has come to encompass many different 
separation techniques and technologies. Numerous LC methodologies have been utilized 
in concert with mass spectrometry over the years,86 however none have had the impact of 
high-performance liquid chromatography87 (HPLC). HPLC/MS has proven to be an 
extremely powerful tool in the analysis of the pharmaceutical compounds.88,89 
 
The typical HPLC consists of a one or more high pressure liquid pumps, a sample 
injector (manual or automated) a chromatographic column (often contained in an oven) 
and ultimately a means of detection.90 In this way the generalized schematic 
representation if an HPLC is itself very similar to the GC before it. As the name implies, 
the greatest contrasts between the modern HPLC and modern GC is the mobile phase 
they employ and the means by which they ultimately achieve separation. While the GC 
relied on a single gas to carry the analyte, the modern HPLC relies on a system of pumps 
(minimally binary, often quaternary) to deliver a precisely mixed mobile phase.91 The 
ability of an HPLC system to accurately dispense these solvents proves critical to the 
robustness of the instrument.92 In the GC, the limited heat capacity of the gas coupled 
with the low mass of the chromatographic capillary allowed separation to be repeatably 
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achieved by simply varying the temperature of the column oven.93 While many HPLC 
instruments are now equipped with column ovens themselves, their function is more to 
mitigate variations in laboratory temperature than to singularly achieve separation. 
 
While variations on the classical methods exist, the HPLC generally achieves 
separation through the use of a compositional gradient of a polar (often H2O) and organic 
mobile phase.94 Most modern laboratory implementations of HPLC/MS for the analysis 
of sample purity or composition begin with the analyte of interest being dissolved in a 
small volume of compatible solvent95 (H2O, CH3OH, ACN)*. The chromatographic 
column, containing the stationary phase, is allowed to initially equilibrate (both thermally 
and compositionally) and the sample is introduced into a highly aqueous matrix. Over the 
duration of the chromatographic run the composition of the mobile phase is slowly 
ramped from a highly aqueous to that of a highly organic nature.96 During this process, 
components of the analytical amalgam which were previously retained on the stationary 
phase slowly become more compatible with the mobile phase, partition, proceeded 
towards chromatographic equilibrium (begin migration) and are eventually eluted from 
the stationary phase as separate species.97 These distinct chemical species are then 
detected or analyzed (MS) to ultimately evaluate the effectiveness of the chromatic 
process. 
 
 While in many ways the MS has become the most informatically rich detector 
available to the typical analytical laboratory, most HPLC systems are equipped with 
detection strategies complimentarily orthogonal to spectrometry. As many laboratories 
are limited by both available instrument time and sample quantity many instrument 
manufactures have made significant strides to provide systems capable of utilizing 
multiple detection strategies during a single run. 
 
 
Ultra-Violet/Visible Detector (UV/Vis) 
 
UV/Vis is in many ways the most obvious compliment to the MS due to the 
nondestructive nature of this detector.  In a typical UV/Vis, the chromatographic elutant 
enters the detector’s transparent flow cell where it is exposed to ultraviolet or visible 
irradiation at a known wavelength.98 Analytes which contain π or non-bonding electrons 
are able to absorb energy through the transitioning of electrons to higher anti-bonding 
molecular orbitals.99 The absorption of energy can be recorded and spectra generated, in 
concert, UV and MS spectra have proven to be a powerful tool in the analysis of 
pharmaceutical compounds.    
 
______ 
*As this introduction is largely devoted to mass spectrometry, reverse phase HPLC will 
be introduced as it is vastly more compatible with traditional MS instrumentation than 
other conventional elution systems.   
  
 12 
Evaporative Light Scattering Detector (ELSD) 
 
 While ELSD is a destructive analytical technique, it has gained great popularity 
for its ability to evaluate many compounds which typically ionize poorly via MS.100 The 
ELSD is also somewhat unique in its ability provide a relatively linear signal response 
independent of the optical properties of the molecule analyzed, in contrast the Uv/Vis 
was only compatible with analytes that contained an accessible chromophore.101 When 
compared to a MS, the ELSD is quite simplistic. The elutant flow is introduced into the 
ELSD nebulizer and mixed with large volumes of nitrogen gas to produce a diffuse 
plume of effluent. The plume is then directed down a heated evaporation tube where the 
remaining mobile phase is rapidly eliminated, leaving only diffuse particles of dried 
analyte.102 The particles of dry analyte are directed through an optical chamber where 
they occlude a high intensity light source. This loss of signal can be recorded and spectra 
generated much as is the case with the Uv/Vis.  
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CHAPTER 2.    HRMS BASED INVESTGATION OF BACTERIAL SECONDARY 
METABOLITES 
 
 
An Introduction to Bacterial Secondary Metabolites  
 
 Like their human hosts, pathogenic bacteria utilize a system of complex strategies 
by which they obtain the nutrients and energy necessary for survival and reproduction.  
Most bacteria assimilate the organic molecules they require to thrive from their 
environment. In this way pathogenic bacteria reap organic molecules from their host 
organism, consume the portion they require, and secrete the waste byproducts as primary 
metabolites.103 
 
 By contrast, secondary metabolites are compounds produced not as a function of 
survival, but as a function of competition. The list of known bacterial secondary 
metabolites has become quite long, and have been used both primarily and as synthetic 
scaffolds for; antibiotics (penicillin), pigments, immunomodulators (of which this chapter 
is concerned), pesticides (pyrethrins) and antitumor agents.104 Two pathogenic 
microorganisms of particular interest to our laboratory are Francisella tularensis and 
Mycobacterium ulcerans (and will be introduced in detail later in this chapter.)   
 
 
Decoupling of Nondestructive (NMR) and Destructive (MS) Analytical Techniques 
 
 While this chapter serves to illustrate two pathogens of particular concern to our 
laboratory, the overarching goal of our bacterial natural product (BNP) effort was not 
solely to investigate F tularensis and M ulcerans. The primary focus of these efforts was 
to establish a universal means of profiling unknown bacterial natural products regardless 
of their species of origin. The resulting workflows were designed in such a way as to 
leverage nondestructive analytical techniques, such as crude extract NMR, to enable the 
targeted application of destructive, more informatically rich techniques. The initial proton 
and 2D crude lipid NMRs coupled with sample conserving analytical TLC provide 
information on the chemical species contained in the BNP while selective TLC 
developing agents, such as Sigma Phospray, can support and enumerate NMR results.  
 
 In this workflow data acquired through minimally invasive techniques can target 
the application of HPLC or Flash chromatographic fractionation as well as conventional 
UPLC/MS analysis depending on the quantity of sample available for analysis  
(Figure 1). In the case of SchuS4, its highly virulent nature precluded the acquisition of 
large analytical stocks. For this reason our workflow was updated to allow for the pooling 
and serial concentration of analyte limited products (Figure 2). Once sufficient quantities 
of analytical samples have been compiled, High Content NMR experiments (HSQC, 
HMBC, COSY, NOESY) coupled with HRMS accurate masses can be applied to the 
enumeration of potential chemical formula For this reason analytical techniques in this 
section will be presented in order of chemical invasivity from the least destructive 
(NMR) to the most destructive (FAME) techniques following our BNP protocols.  
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Figure 1. Pictorial Representation of SchuS4 BNP Analytical Workflow 
Illustrating the Extraction, Separation and Analysis of Bacterial Natural Products  
 
NOTES: SchuS4 / LVS were harvested and acetone soluble lipids (ASL) were removed 
and dried. The dry ASL was redisolved in MeOH and deactivated silica 60 A (1g) added, 
the resulting mixture was then evaporated to dryness via rotovap, the lipid impregnated 
silica was transferred to the top of a 4 g HP-Sil (Biotage) cartridge for flash 
chromatography using a eluent gradation of 90% CHCL3/ 10% CH3OH to 60% CHCL3/ 
40% CH3OH, all fractions were collected and content monitored via by TLC analysis. 
The lipids potential for immune modulation of each fraction was bio-assayed, fractions 
retaining biological activity were further analyzed using UPLC-qTOF.  
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Figure 2. Detailed Workflow for the Separation and Analysis of Product 
Limited Francisella tularensis Extracts  
 
NOTE: The addition of an offline sample store allows archival of analytical stocks until 
sufficient concentrations have been achieved through serial fractionation and pooling 
efforts.  
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Introduction to Francisella tularensis 
 
F tularensis (Ft) is a pathogenic gram-negative bacteria which causes the disease 
Tularemia in humans. As the pathogen is readily transmissible by aerosol and highly 
virulent it has been classified as a Class A Select Agent in the United States.  Ft is also 
unique from a metabolic tractability standpoint as the virulent SchuS4 strain and non-
virulent live vaccine strain (LVS) appears to retain very similar (though distinct) lipid 
profiles. Recent work in the Bosio Laboratory at the National Institutes of Health has 
shown lipid extracts from FT when administered to stimulated murine bone marrow 
derived microphages (BMM) significantly attenuated the inflammatory cytokine 
response. This attenuation suggested that the extracts from the SchuS4 strain contained 
an immune suppressive substance. Interestingly, Ft lipids have also shown to elicit 
protective immunity in MyD88 -/- mice through the surface expression of Lipid A 
analogs.105 When separated into a ternary system via modified Folch106 partitioning, the 
majority of the attenuating agent remains in the chloroform fraction, supporting the 
hypothesis that SchuS4 lipids are important virulence factors (Figure 3). 
 
Preliminary testing revealed the lipids from the virulent Ft SchuS4 strain 
displayed a significant affinity for cytokine attenuation while similarly prepared lipids 
from the attenuated Ft live vaccine strain (LVS) showed little to no effect. Initial samples 
of dried lipid were suspended in CDCl3 and submitted for proton NMR (Figure 4). Small 
lipid peaks may be resolved but the crude lipid was found to be highly contaminated with 
bacterial cellular debris, 2D NMR also proved quite complex (Figure 5). The crude lipid 
was separated via 2D TLC as well as fractionated by standard phase flash 
chromatography in an attempt to reduce background contamination. A portion of the 
fractionated materials were returned to NIH for testing, the areas of high activity were 
pooled and further analyzed via LC/MS. Traditional and 2D TLC’s of Schus4 and LVS 
lipid crudes were run using a semi-analytical technique (Figure 6) the bioattenuation 
properties were then evaluated (Figure 7), this data provided us the ability to locate the 
“most active” components for further “destructive” analysis.  
 
Guided by cytokine deactivation potential of SchuS4 (Figure 8) as compared to 
the LVS profile (Figure 9), fractions were concentrated into three pools. As fractions 
were separated via normal phase silica gel chromatography the pools were generated 
based upon the polarity of the analyte. The highly nonpolar (Fractions 4-5), the 
moderately polar (Fractions 19-23) and the most polar (Fractions 28-34) pools were then 
submitted for further analysis. (Figure 10) Following the BNP workflow lipid fraction 
pools were first analyzed via nondestructive techniques (NMR, UV). These data were 
then used to guide the application of more intrusive chemical analysis 
(HPLC/MS)(GC/MS). Processed NMR and UPLC/MS spectra of the nonpolar pool are 
illustrated below. Figure 11 is a processed spectra from 1024 scan proton NMR. After 
primary fractionation the spectra remains complex though appears to contain significant 
concentrations of saturated lipids (1-2 ppm) and reduced concentrations of unsaturated 
lipid products (4.0-4.7 ppm). Figure 12 illustrates a processed 2D HSQC of this sample, 
when compared to the unfractionated sample the fatty acid and phospholipid regions 
appear to have increased relative to the aromatic component.   
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Figure 3. Activity of Modified Folch SchuS4 Partitioned Lipids with and 
without Addition of the Cytokine Activating LPS, with the Chloroform Fractions 
Predominately Responsible for Cytokine Attenuation  
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Figure 4. Complex Proton NMR Spectra of Crude SchuS4 Lipid Extract with 
Lipid Signals Largely Masked  
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Figure 5. Complex 2D NMR of Crude SchuS4 Lipid Sample 
 
NOTE: The fatty acid region remains highly complex. 
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Figure 6. Illustration of Typical SchuS4 Lipid 2D TLC 
 
NOTES:  Black line indicates the point of origin; the analytes were first eluted in (12:6:1) 
CHCl3:MeOH:H2O.  The plate was rotated 90◦ and again separated via (10:6:4:1) 
THF:1,2-Dimethoxymethane:MeOH:1M NH4OH. 
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Figure 7. Bioanalysis of SchuS4 2D TLC Bands (B1-B5) at 1:100 and 1:300. 
 
NOTE: Dilutions indicate TLC Band 1 retains significant cytokine attenuation potential 
in primary murine BMM cells. 
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Figure 8. Cytokine Deactivation Potential of Initial Flash Chromatographic 
Fractions of SchuS4 Lipid Extract 
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Figure 9. Cytokine Deactivation Potential of Initial Flash Chromatographic 
Fractions of LVS Lipid Extract 
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Figure 10. Cytokine Deactivation Potential of Initial Flash Chromatographic 
Fractions of SchuS4 Lipid Extract Illustrating Three Areas of Activity  
 
NOTE: Fractions 4-5, 19-23 and 28-34 were pooled for further analysis. 
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Figure 11. 1024 Scan Proton NMR of Pooled SchuS4 Fractions 20-24 
 
NOTE: The saturated and unsaturated regions of the spectra remain highly complex. 
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Figure 12. 2D HSQC of Pooled SchuS4 Fractions 20-24 Depicting the 
Enrichment of Fatty Acids and Phospholipids  
  
 27 
Fatty Acid Methyl Ester Derivatization and GC/MS Analysis 
 
As many of these experiments predated our laboratories acquisition of a HRMS, 
Figure 13 depicts a processed UPLC-SQD spectrum of the concentrated nonpolar lipid 
pools of LVS and ScghuS4 lipid. The peaks at 581.2 m/z (butylstyrene) and 463.3 m/z 
(polypropylene)(Figure 14) appear to be highly significant but were later determined to 
be common laboratory contamination. Additional analysis revealed lipids were likey 
present in the very polar pool however they appeared to be poorly ionizable and similarly 
contaminated via ESI-LC/MS (Figure 15). At this point in the investigation a decision 
was made to temporally discontinue the use of LC/MS in favor a of GC/MS based fatty 
acid methyl ester (FAME) workflow as the derivatization process (HCl-MeOH or KOH) 
would largely disregard the observed laboratory contamination.  
 
Fatty Acid Methyl Esterification GC/MS analysis enabled direct evaluation of 
SchuS4 and LVS matched acetone soluble lipid (ASL) crude lipid samples without the 
sample diminishing chromatographic step. Methyl esters of the ASL lipid crudes were 
prepared by transesterification using HCl-CH3OH or base catalyzed (KOH or TBAH) 
iodomethane methylation. The resultant spectra were analyzed by GCMS using a BD-225 
column and 42 minute thermal gradient from 90◦ to 220◦C. Elutant peaks were compared 
to NIST spectral database for peak identification. Upon comparison the SchuS4 and LVS 
spectra are quite similar (The LVS Peak 8 tailing is due to the aforementioned preexisting 
contamination) except for the large decanoic acid peak (2) completely absent from the 
LVS sample. The processed spectra for LVS (Figure 16), SchuS4 (Figure 17) and 
composite LVS/SchuS4 (Figure 18) are presented below. 
 
The results from the TBAH derivatization largely confirmed the results from the 
acidic experiments; peak 2 appeared to be significantly larger in the virulent strain, while 
peak 4 appears to be significant enlarged in LVS. The processed spectra for LVS (Figure 
19), SchuS4 (Figure 20) and composite LVS/SchuS4 (Figure 21) are presented below. 
Peaks A-D corresponds with the butyl esters of previously identified compounds. The 
TBAH difference maps (Figure 22 and Appendix B) also suggest that SchuS4 may be 
additionally enriching tetra and octadecenoic acid components of its lipid membrane. 
Upon further investigation, decanoic acidtetradecanal is generally accepted to be a 
function of bacterial membrane plasticity generally associated with bacterial remodeling 
of the lipid membranes in response to temperature (as temperature decreases the 
bacterium installs shorter chained lipids to maintain membrane plasticity).107 
 
 
Ft Lipid Conclusions and Discussion 
 
The purpose of the original lipid workflow was to use nondestructive means to 
more accurately target more destructive analytical techniques. The single and multi-
dimension NMR work illustrated the lipids of interest resided in a complex matrix of 
cellular and laboratory contamination. The use of semi-preparative LC allowed lipid 
fractions to be tested discretely; however, the absolute recovery suffered greatly as the 
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Figure 13 Serial Concentration UPLC/MS of Non-polar LVS (Top) and SchuS4 
(Bottom) Fraction Pools  
 
NOTE: The two significant SchuS4 peaks at 581.4 m/z (Butylstyrene) and 463.3 m/z 
(Polypropylene) were determined to be laboratory contaminates.    
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Figure 14. Extracted Spectra from TR 4.323 (463.3 m/z) Δ 44m/z Indicative of 
Polypropylene Contamination 
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Figure 15. The Data Directed (MSe) TIC of SchuS4 Fractions 29-34 Displayed 
Similar Contamination 
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Figure 16. GC/MS Spectra of HCl-CH3OH Fatty Acid Methyl Ester 
Transesterification Products of LVS Acetone Soluble Lipid Extract  
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Figure 17. GC/MS Spectra of HCl-CH3OH Fatty Acid Methyl Ester 
Transesterification Products of SchuS4 Acetone Soluble Lipid Extract  
 
NOTE: Peak two is of particular interest. 
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Figure 18. Composite of GC/MS (HCl-MeOH) Fatty Acid Methyl Ester 
Transesterification Products of SchuS4 (Positive) and LVS (Negative) Acetone 
Soluble Lipid Extracts 
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Figure 19. GC/MS Spectra of Base Catalyzed (TBAH) FAME Products of LVS 
Acetone Soluble Lipid Extract 
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Figure 20. GC/MS Spectra of Base Catalyzed (TBAH) FAME Products of 
SchuS4 Acetone Soluble Lipid Extract 
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Figure 21. Composite of Base Catalyzed (TBAH) FAME Products of LVS 
(Positive) and SchuS4 (Negative) Acetone Soluble Lipid Extracts 
 
NOTE:  Difference maps were normalized for tetradecanoate.  
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NOTES: In an attempt to futher validate SchuS4’s proposed enrichment of peak two, a 
KOH supponification was attempted. Upon investigation, the only meaningful difference 
was in docosanoic acid (Peak 11)--further suggesting some divergences in the lipid 
profiles of the bacteria are likely resultant from differences in their environment (BSL2 
vs BSL3).  
  
 
 
Figure 22. GC/MS (KOH) Fatty Acid Methyl Ester Transesterification Products 
of SchuS4 (Positive) and LVS (Negative) Acetone Soluble Lipid Extracts Normalized 
for Tetradecanoate 
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analytes are moderately soluble at best. The GC work served to illustrate a number of 
interesting results, SchuS4 expresses significantly more short chained (12:0/14:0) acids, 
while LVS appears to express longer chains (18:0). While a portion of this expression is 
likely a result of membrane homeostasis, it is interesting to note Lipid A surface 
expresses predominately (18:0) and Lipid A mutation has shown to play an important 
role in potentially protecting immune compromised mice.105   
 
 TLC/LTQ-MS experiments were designed and are currently underway to 
determine if the methyl esters identified via GC are part of a larger conjugated molecule 
(Lipid A) or if they exist as smaller free lipid species. 
 
 One of our primary goals in the design and implementation of the SchuS4 / LVS 
lipid analytical workflows was to leverage a number of nondestructive analytical 
techniques to target destructive, though informatically rich, mass spectrometric analyses.  
The preliminary NMR and TLC data provided considerable data including the presence 
of fatty acid components and common laboratory contaminates. In retrospect, as the LVS 
lipid components are expressed and purified in standard laboratory glassware (BSL1+) 
while the growth of virulent SchuS4 requires elevated precautionary measures (BSL3+) a 
few of which are the exclusion of glassware and use of plastic cultureware, a certain level 
of plastics and plasticizer contamination in the SchuS4 extracts was unavoidable.   
 
 Initially we sought to overcome this contamination through the use of semi-
preparatory flash chromatography. Three pools of SchuS4 fractions retained tractable 
activity upon separation, however the limited solubility if the lipid products greatly 
diminished recovery. We realized from the outset any chromatographic system would 
afford analytical losses. Our hope was the acquisition of highly meaningful correlational 
2D NMR would prove the sacrifice worthwhile. Unfortunately the 2D spectra remained 
highly complex and inappropriate for correlational spectroscopy, as multiple peaks 
overlapped in key areas. 
 
 The GC transesterification proved highly successful to study lipid content as it 
required little analyte and the chemical derivatization and chromatographic separations 
removed many of the existing contaminates. The discovery of the short chain fatty acids 
(SCFA) found only in the SchuS4 extract is thought to be highly significant. 
The question now is to determine if these SCFA lipids exist on their own functioning as 
immunesuppressive agents or if they are conjugated into macromolecules for example 
Lipid A or if both may be true.  The biological basis for either chemical theory appears 
conceivable as the limited genetic material available (2.3 Mb) suggest Ft is genetically 
unable to afford many of the more advanced defense mechanisms via the synthesis of 
complex polyketides or non-ribosomal peptides as witnessed in larger pathogens such as 
P. aeruginosa and M. ulcerans.   
 
Over its evolutionary history as a pathogen Ft has developed many tools to 
subvert host immune response. The question now is do host immune bodies fail to 
recognize the impending threat? Or are they somehow deactivated through a small 
molecule modulator? The surface expressed lipid A head of LPS is a primary determinant 
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of antigenic response to gram negative bacteria. A recent publication noted Ft’s ability to 
remodel Lipid A.105 If the Lipid A antigen were adapted to express SC fatty acids as 
opposed to the more usual 18:0 and 20:0 systems it is interesting to hypothesis that the 
host immune bodies via innate Toll signaling pathway may not be activated by virulent 
strains of Ft, at least for a time.  
 
 To this end a TLC/Direct Injection LTQ-MS experiment was developed in an 
attempt to conclusively identify the SCFA conjugation products of Ft SchuS4. While we 
only have preliminary data at this time, the initial results appear to confirm the 
experimental design. The phosphatidylethanolamine (Figure 23) head group contains 
seven carbons, the spectra indicates 32 to 36 total carbon (Figure 24), as there are 
generally symmetric-2 lipid prosthetics the lipid moieties appear to range from 10 to 14 
carbons in length supporting results from our GC-MS analysis. We have also identified 
phosphotidylcholine (Figure 25) though it displays a more usual lipid chain length.108 
 
 
Development of a Generic Bacterial Natural Product Analytical Workflow with 
Applications from the Analysis of Mycolactone 
 
The analysis of bacterial natural products (BNPs) presents a number of somewhat 
unique challenges to the laboratory chemist, many due to the amazing diversity inherent 
to NP libraries. While no consolidated BNP evaluation workflow currently exists, there 
are a number of proven analytical techniques directly compatible to work in BNP 
isolation and classification. An unfortunate caveat exists throughout many of these 
analyses, however, in that a pure analytical sample is predominantly required to generate 
meaningful data.  To this end, many BNP workflows are subdivided into two primary 
components; purification and analysis. 
 
 The primary focus of our purification technique is to separate the unknown 
complex fraction into multiple, reasonably pure fractions, while recovering as much of 
the initial analyte as possible. Conceptually, this technique may be applied in one of two 
ways; the bulk fractionation of a complex mixture (as is often the case when working 
with large quantities of crude material or in industrial applications) or an analytically 
driven “targeted fractionation” approach. Given the relatively limited quantity of analyte, 
a target driven fractionation approach appears to be the most prudent.   
 
 
 
 
 
 
 
 
 
 
Figure 23.  Structure of Phosphatidylethanolamine Head Group 
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Figure 24. LTQ-MS of Phosphatidylethanolamine 
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Figure 25. LTQ-MS of Phosphotidylcholine 
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 The primary focus of our purification technique is to separate the unknown 
complex fraction into multiple, reasonably pure fractions, while recovering as much of 
the initial analyte as possible. Conceptually, this technique may be applied in one of two 
ways; the bulk fractionation of a complex mixture (as is often the case when working 
with large quantities of crude material or in industrial applications) or an analytically 
driven “targeted fractionation” approach. Given the relatively limited quantity of analyte, 
a target driven fractionation approach appears to be the most prudent.   
 
As the fraction of interest appears to contain a chemical species affording high 
activity against a particular bioassay, a bioactivity driven secondary fractionation may 
offer the best odds of identifying the active compound, also as the identity of the plant is 
known, a literature search may be useful in identifying previously isolated active 
components. Over the past two years, our lab has taken interest in the bioactivity driven 
fractionation of naturally derived compounds, if a selective bioassay exists, they often 
afford levels of detection far superior to traditional analytically driven techniques.   
 
 Some limited MS data can be greatly helpful in preparing for a secondary 
fractionation run. A small aliquot of material sampled on the HRMS in both ESI(+) and 
ESI(-) full scanning mode offers insight into compound polarity (this aided by initial 
fractionation conditions and elution time) apparent ionization efficiency and fraction 
complexity. In a somewhat method and analyte dependent fashion, the pKa of a 
compound may be estimated by comparing its elution time against a series of known 
compounds, in much the same way as gel based systems use molecular weight “ladders” 
to qualitatively identify the molecular mass of an unknown protein. While single point 
data may provide useful, these estimations become more robust with the inclusion of 
orthogonally referenced elutions. Aided by these estimations, the empirically measured 
high resolution mass data can be used to predict prospective chemical formula for the 
NPs while the UV detector offers secondary detection of compounds containing 
accessible UV chromophores.  
 
 The secondary fraction of a BNP is conceptually quite simple but often difficult to 
achieve in a laboratory setting. The hope is to separate the BNPs using a method more or 
less orthogonal to the original (Standard Phase CHCl3:CH3OH) fractionation conditions. 
We have evaluated a number of semi-analytical chromatographic conditions for their 
ability to provide selectivity contrasting with CHCl3:CH3OH separations. While HILIC is 
often referenced as a hybrid of conventional and reverse phase chromatographic 
techniques (for its reversal of conventional RP elution orders) we have been unable to 
achieve reasonable recoveries with this technology. 
 
In our laboratory we have relied on Phenomenex pentafluorophenyl (PFP) 
stationary phase chemistries to provide a somewhat contrasting separation technique 
compared to conventional C18 (PFP is a reverse phase column and uses mobile phases 
similar to C18 but is specially hybridized by the inclusion of a polar-cyclic 
pentafluorophenyl motif that differentially retains many of the aromatic and polar 
compounds often encountered in natural products). While we have found success using 
this type of secondary fractionation, especially when the samples are not overly complex, 
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I feel the investigation of a truly orthogonal separation technique is warranted and will 
increase the robustness of any subsequent BNP publications. To this end, I am currently 
investigating semi-analytical SFC based techniques for their potential application to our 
BNP workflow.   
 
Both techniques offer potentially complimentary selectivity, however, I have 
found many of my standard phase BNP separations often offer low recoveries when 
analytes are in the milligram range, we have recently acquired low volume (4 gram) 
deactivated silica columns for use with our isolera flash chromatography systems which 
should aid in sample recovery. We are currently evaluating a BNP workflow in which the 
primary preparative fractionation relies on standard phase ELSD coupled deactivated 
silica “flash” chromatography while subsequent semi-preparative steps utilize traditional 
C18 based separations; thus far, this methodology appears to provide a truly 
nonequivalent, complimentary separation technique.  
 
In similar fashion, I believe a SFC based semi-preparative approach may be most 
orthogonal to the C18 based primary separations. This might also prove to be 
advantageous over our standard phase techniques, as SFC potentially offers both 
increased recoveries and avoids the difficulties associated with the handling and 
desolvation of CHCl3. From this point in the analytical workflow HRMS data coupled 
with one of the previous semi-preparative techniques should prove sufficient to separate 
the initial complex hit into a number of relatively pure fractions. These high purity 
fraction(s) should then be re-submitted to the bioactive assay to locate the fraction(s) 
responsible for the initial hit. Once high purity fraction(s) are recovered, a number of 
analytical techniques become available for the evaluation of the active chemical 
compound(s). 
 
The analysis of BNP components often relies on two very different analytical 
approaches, NMR and MS. Many labs, including our own, often submit chemical hits to a 
somewhat standardized NMR analysis prior to conducting any MS work. NMR based 
BNP analytical techniques greatly benefit from the nondestructive nature of the NMR, 
coupled with the fact any materials transferred to dueterated solvents may be easily 
analyzed via MS. While NMR experiments are more contingent upon the recovery of a 
sufficient sample (1-2 mg for proton, 2-5 mg for conventional 13C, 10 mg or more for 
correlational studies), they offer a potential array of chemical information from simply 
the number of carbons and hydrogens contained by a compound to detailed structural 
information from spin correlational or NOE type experiments through a nondestructive 
means.   
 
Once the NMR work has been completed the MS work may begin, as mass 
spectrometry is inherently a destructive technique, care must be taken in the sequencing 
of the MS analyses. I often acquire another HRMS ESI(+) and ESI(-) full scan (Figure 
26) of the active re-fractionated samples to provide a point of reference for future 
analyses, as before, prospective chemical formula(s) may be generated from the high 
resolution isotopic and mass defect measurements. From this point, the analytical 
workflow may fork into two possible directions, one includes operating the HRMS in a 
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Figure 26. UPLC Targeted TQD-MS/MS of Control Mycolactone (765.4 m/z) 
Served to Validate MS/MS Quantification Techniques 
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way as to effectively overvolt the sample cone (octopole) thereby inducing nonspecific 
electronic fragmentation (in this way essentially mimicking the collision cell on the 
TQD), the second relies on the use of the TQD to induce kinetic fragmentation at/in its 
Q2 collisional cell. (Figure 27 illustrates the kinetic induced fragmentation of the parent 
mycolactone, 765 m/z, to the mycolactone core, 429 m/z, before (A) and after (B) 
exposure to sunlight.) (Structure of mycolactone provided in Figure 28) Electronic and 
kinetic fragmentation experiments are often complimentary in the profiles generated. The 
HRMS induced fragmentation experiments may be conducted while running the 
previously discussed full scans, in this way, a great deal of information may be gleaned 
from a limited amount of analyte. 
 
Traditionally the neutral losses (NL) in an unknown analytes kinetic 
fragmentation spectrum have been used to provide insights into a molecule’s 
fragmentation motifs and its ultimate functionalization. In the case of the TQD, these 
experiments may be conducted through the utilization of NL scans or through the 
creation of MRM experiments. These single or multiple reaction monitoring 
(SRM,MRM) processes rely on their ability to preselect one or multiple parent 
molecule(s) at the first quadrupole (Q1), subject this parent molecule to a kinetic 
fragmentation event (Q2) and then analyze the resultant fragments through the use of a 
final scanning quadrupole (Q3). (In a careful experiment, the kinetic potential of Q2 can 
be tuned to allow for the enrichment of the mycolactone core while providing sufficient 
molecular ions to discriminate between mycolactone (765 m/z) and 
tetrahydroxymycolactone (747 m/z). The net effective fragmentation event can then be 
ramped to provide fragments in an ascending order from the most electronically 
accessible functional groups to the more shielded molecular scaffold.   
 
In this way the TQD’s capability to precisely control the fragmentation process 
provides the analytical chemist a powerful tool in the ability to back-calculate many 
pieces of a molecule, as noted, the HRMS may be used to provide a similar but much less 
precise fragmentation process. This serves to illustrate a theme expressed throughout NP 
work; data rich MS experiments are often sample rich as well, the HRMS fragmentations 
are useful as they provide much of the TQD NL/MRM data while only consuming a 
fraction of the sample necessary to construct a conventional MRM experiment.   
 
 
Introduction to Mycobacteria ulcerans 
 
 The causative agent of Buruli ulcer, Mycobacterium ulcerans (Mu), is the third 
most common form of mycobacterial infection in humans after only TB and leprosy.109 
The early stages of ulcerans infection often manifests as a small, dermal papule. Without 
proper diagnosis and treatment, the bacterium slowly invades and necrotizes the 
surrounding tissues through the secretion of the toxin mycolactone.110 (Figure 28). As the 
affliction of Buruli ulcer is primarily concentrated in developing nations located in 
tropical areas of the world111 a number of laboratories, ours included, have been 
investigating the possibility of a low cost means by which to remediate the progression of 
ulcerans infection. 
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Figure 27. Targeted UPLC-TQD-MS/MS of Mycolactone Subspecies 747.4 m/z 
(Top) and 765.5 m/z (Bottom) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 28. Structure of Mycolactone (m/z=765) 
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Several laboratories (including our own) have noted the instability of isolated 
mycolactone.112 In collaboration with the Britton laboratory we further investigated the 
effects of natural and UV light on mycolactone stability and sought to evaluate the 
potential clinical relevance of such findings as a low cost approach to remediate the 
effects of mycolactone toxification. While our collaborators113 were primarily concerned 
with the in-vivo and in-vitro modeling of mycolactone photoablation, our laboratory aims 
were to isolate sufficient quantities of mycolactone and study the effects of UV and 
visible  photo irradiation on the chemical composition of the toxin. The impure M. 
ulcerans lipid extracts were separated and analyzed for purity following a (now 
standardized) BNP workflow. Secondly, the photostability of mycolactone was assessed 
via mass spectrometric tools.    
 
In a proof of concept experiment, methanolic solutions of our internally produced 
pure mycolactone were applied to transparent plates and slowly rotated until a thin film 
developed. The plates were then randomly divided into two groups, light and dark. The 
light group would be exposed for 30 to 120 minutes of “Memphis Sun” (atop the hospital 
parking deck at 1:00 PM on cloudless days throughout May and June with an outside 
temperature ranging between 78◦ and 89◦F, controls were allowed to remain outdoors 
covered in ablative foil during the exposure in an attempt to differentiate thermal and 
photo-induced degradation processes). The thin films would be resolvated in CH3OH and 
divided for bioanalysis and MS (Figure 29) illustrates the conservation of 765 m/z to 429 
m/z (indicative of mycolactone) prior to exposure to sunlight (A), the daughter peak was 
lost post-exposure (B) indicating the disruption of the polyene system. The bioanalytical 
technique involved treating human keratinocytes with aliquots of the light (E) and dark 
(F) mycolactone samples, while kill curves remained similar; the light group required a 
half-log increase in dose to achieve similar toxicity (Figure 30). In a comparison of 
mycolactone toxicity between batches (Figure 31) the new mycolactone stocks 
demonstrate significantly increased toxicity, illustrating the inherent instability of 
mycolactone thin film archival. While the structure of mycolactone was previously 
known, an effort was made to assay the analytical invasivity of our techniques due to the 
light sensitive nature of the compound. There was initial concern the UV/Vis detector 
might be capable of degrading the mycolactone under analysis (Figure 32), this proved to 
not be a concern as mycolactone parents 755 m/z and 747 m/z were unaffected, as no 
significant change in peak area was observed. 
 
 
Mycolactone Conclusions and Discussion  
 
 The recent publication by Marion112 in many ways supports the findings of this 
work as well as suggesting a number of potential modifications to our current 
mycolactone production and storage strategies.  We have successfully shown 
mycolactone’s toxic potential is mediated through the exposure to sunlight. We were able 
to determine indoor light was harmful, though not nearly to the extent at sunlight (as 
confirmed my Marion).  We determined conclusively UV/Vis flow spectrometry does not 
significantly damage mycolactone, likely due to the shielding effects of the effluent.  We 
were also able to develop robust TQD based assays for both quantification and  
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Figure 29. 765 m/z Daughter Scan Indicating the Presence of the Mycolactone 
Core (429 m/z) Prior to Sunlight Exposure (A) and Post Exposure (B) 
 
NOTE: Post exposure, the parent/daughter transition indicative of mycolactone could not 
be detected. 
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Figure 30. The Effect of Mycolactone Photoablation on Human Keratinocytes  
 
NOTE: The UV exposed mycolactone stock (F) suffers a 0.5 log reduction in toxicity as 
compared to the control mycolactone (E).   
  
 50 
 
 
 
Figure 31. The Effect of Two Mycolactone Lots on Human Keratinocytes  
 
NOTES: Both mycolactone lots were archived as thin films demonstrating mycolactone 
suffers significant detoxification while stored as a film.  The time differential between 
batches was 131 days.  
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Figure 32. Analysis of Mycolactone Stability via Differential Red (Top Set) and 
UV (Bottom Set) Light Flow Spectroscopy of m/z 747 (Upper) and m/z 765 (Lower)  
 
NOTE: No significant photoablation was detected in the UV/Vis flow cell exposed 
samples.  
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classification of mycolactone subspecies, though we were unable to detect any significant 
mycolactone degradation products (Marion also failed to report any significant 
mycolactone photodegradation products and instead worked to assay primarily through 
spectroscopic means).   
 
 The Marion article also suggests a few improvements may be made to our 
framework.  As our mycolactone efforts are shared by both national and international 
collaborators, the decision was made to store, assay and ship our mycolactone stocks as 
thin films.  The reasoning was thin films would both reduce the accidental dissemination 
of highly toxic materials as well as greatly simplify the process of shipment.  (The 
international shipment of highly toxic liquids is an extremely laborious and expensive 
process)  Marion found storage as a thin film to be the least appropriate means of 
mycolactone archival due to proposed dehydration effects, mycolactone was found to be 
most amenable to archival in ACN at low concentrations. 
 
 While the article makes no effort to differentiate between the photoablative and 
chemical processes responsible for mycolactone’s amazingly short half-life as a film, it 
will be interesting to determine if variations in our production and storage processes 
persists after transitioning to solution based archival. 
 
Buruli ulcer, the human affliction associated with the mycolactone excreted by M 
ulcerans as it attempts to evade the immune responses of its unwilling host, is an 
affliction largely borne by developing nations in tropical regions. While our initial 
laboratory efforts were simply concerned with culturing ulcerans for the production of 
mycolactone as a chemical probe, a number of our collaborators sought to leverage our 
knowledge in the effort to combat Buruli. The chemotherapeutic treatment for Buruli 
ulcer is the combinative administration of rifampicin and streptomycin, the intramuscular 
administration route and relatively short shelf-life of these drugs preclude their clinical 
application in many parts of the world. As a number of early efforts to characterize 
mycobacterial secretions (including our own), observed a sensitivity to light. An effort 
was undertaken to evaluate sunlight’s ability to detoxify (and possible reverse) 
mycolactone associated necrosis. Clinical investigations are currently being conducted by 
the Britton group in Ghana and initial results appear promising.  
 
 As noted prior as, the optimal storage conditions for the archival of mycolactone 
was recently published.112 Based upon these findings, our decision to store our 
mycolactone stocks as thin films should be reviewed. In light of the thin film stability 
studies I believe many of the variations observed through our purification and analysis 
effort were likely a product of the thin film and not wholly associated with photoablative 
effects, especially in the laboratory. Our next lot of ulcerans should be ready for harvest 
soon and I have already revised the separation protocols to account for the findings of 
Marion.   
 
 To aid in the efforts I would like to continue the evaluation of the in-vitro photo-
mitigation of mycolactone in an attempt to decisively answer lingering questions. While 
mycolactone’s unique polyene system is responsible for the majority of the compound’s 
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UV absorbance (especially at longer wavelengths), no laboratory has currently been able 
to identify the remaining mycolactone fragments post photoablation. While our sunlight 
exposure experiments illustrated the ablative effects of sunlight on mycolactone, I was 
unable to conclusively identify any ablative fragments. I now believe this experimental 
shortcoming to be a function of the thin-film as opposed to the ablative or analytical 
processes themselves. As Marion conclusively illustrated, even very (60 min) periods of 
thin film storage resulted in a very significant reduction in the abundance of the 
mycolactone. In the next iteration of our ongoing mycolactone production and archival 
efforts I will implement the dilute ACN storage and processing techniques Marion found 
to be so successful. The extraordinarily low UV cutoff of high purity ACN will enable 
me to carry out my photoablations while preserving the resultant fragments for HRMS 
analysis and elucidation. 
 
 While the previous aim seeks to determine the most suitable form of UV 
irradiation for mycolactone exposure and its ablative products, I would also like to 
investigate the implications of exposing Buruli ulcer to UV and visible irradiation. Initial 
ulcerans infection presents as a small, seemingly insignificant, dermal papules and over 
an order of weeks to months slowly develops into a necrotic ulcer with germinal 
infiltration114. M ulcerans subcutaneous implications are largely based upon the 
observation that many of the most severe infections are often quite painless, presumably 
due to the toxin invading and destroying the deeply distributed pacinian corpuscles (nerve 
terminals housed deeply in the dermis) The question to me is, as the ulcerans is able to 
slowly encroach upon the human dermis, what form of irradiation would serve to 
deactivate deeply distributed mycolactone while preserving the patient’s already 
compromised skin? As the susceptibility of human dermal tissues to various types of 
nonionizing irradiation is known, the question is how to evaluate the UV penetration of 
Buruli lesion. Collaborations are currently underway to tease out the response of dermal 
infection to irradiation in Ghana via surrogate in guinea pig. I believe these data in 
combination with my ablation findings will aid in the effective development of low cost 
phototherapies for ulcerans infection.  
 
In this way I believe our laboratory can continue to provide high purity 
mycolactone stocks to our international collaborators and in our own little way help to 
curb the global affliction of Buruli ulcer.  
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Experimental Methods 
 
The experimental methods developed throughout this chapter are outlined below.  
 
 
SchuS4 Lipid Methods  
 
 
Total Lipid Extraction 
 
ASL Lipid Extracts were generously provided by the Bosio laboratory. 
 
 
Fractionation of Cell Wall Associated Lipids (Modified Folsh) 
 
A solution of MeOH/0.3% Aq. NaCl(100/10) (5 mL) and Pet. Ether (2.5 mL) was 
added to lipid crude and stirred at 50oC for 30 min then centrifuged to form a partition. 
The organic layer was decanted and additional Pet. Ether (2.5 mL) was added to the 
remaining lipid for an additional extraction. The organic layers were combined and dried 
under a stream of nitrogen. A solution of (CHCl3/CH3OH/0.3% NaCl (90/100/30) (2.5 
mL) was added to the lipid containing vial and again stirred, extracted and partitioned. 
The organic layer was decanted and 1 mL of a solution of (CHCl3/CH3OH/0.3%NaCl 
(50/100/40) was added to the lipid stirred, extracted and partitioned. The organic layer 
was again removed and the extraction was repeated. The organic layers were pooled and 
dried. 2.5 mL CHCl3 and 2.5 mL 0.3% Aq. NaCl were added to the remaining lipid 
mixture and briefly stirred then allowed to partition. Both layers were collected and 
brought to dryness under nitrogen stream. 
 
 
Fatty Acid Methyl Esterification  
 
Methanolic HCl was prepared by adding 7 drops (250 µL) of acetyl chloride to 5 
mL of very dry CH3OH in the fume hood. HCl-MeOH (2 mL) was added to 2 mg of dry 
crude lipid and sample stirred to allow for dissolution. The sample was allowed to react 
overnight, and then dried under a stream of nitrogen. Hexane (2.5 mL) and H2O (2.5 mL) 
were added to the vial to from a partition and the layers were stirred rapidly for 20 
minutes. The hexane layer was removed and additional hexane (2.5 mL) was added and 
stirred. The organic extracts were dried in vacuo, resuspended in CH3OH and analyzed 
via GC/MS.   
 
 
GC/MS FAME Analysis  
 
 GC/MS analyses were performed on an Agilent 5975c Series GC/MSD. All 
samples were diluted in CH3OH prior to injection. An Agilent DB-225 (30m x 250µm x 
0.25µM) silica capillary column was utilized via thermal gradient of 90◦C for 3.5 min, 
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then 4◦C/min to 220◦C for 7 min for a total run time of 43 minutes. Detection was 
achieved via FID and MS. MS was configured and calibrated for “high gain” mode with a 
gain factor of 15, a 5 min solvent delay and was scanned over 50 – 500 m/z.  The EI 
source was maintained at 230◦C while the quadrupole was heated to 150◦C.    
 
 
HPLC Fractionation and Analysis 
 
 All samples were dissolved in GC/MS grade CH3OH and transferred to 
autosampler vials. Separations were achieved on a Phenomenex Luna 5µ C18(2) (250mm 
x 10mm x 5µm) at room temperature, flowing 3.5 mL/min of H20 + 0.1% Formic acid 
(A) and ACN+ 0.1% Formic Acid (B).  The first 12.5 minutes were maintained at 10% 
organic followed by a linear ramp to 95% organic over 45 minutes then held at high 
organic for an additional 12.5 minutes resulting in a 1 hour total chromatographic elution.  
All fractions were collected in glass tubes then turbovaped to dryness. The samples 
flagged through UV and ELSD were reanalyzed via UPLC/MS. Fractions found to 
contain lipid moieties were divided 1:10 for bioanalysis and archival respectively. 
 
 
UPLC/MS Analysis  
  
 LC/MS Analyses were performed on both a Waters Acquity UPLC-TQD and a 
Waters Acquity UPLC-qTOF. All dry analytes were solvated in CH3OH and filtered prior 
to analysis; liquid analytes were diluted in the same and filtered. Separations were 
achieved at 0.5 mL/min via a 5 minute gradient elution from 95% H2O + 0.1% Formic 
Acid to 95% ACN + 0.1% Formic Acid as follows.  The first 30 seconds were held at the 
starting conditions then ramped to 40% organic over two minutes followed by a ramp to 
95% organic an additional two minutes then followed by a 30 second stop at the 95% 
organic before returning to re-equilibrate.  A Waters Acquity C18 BEH 1.7µ x 50 x 
3.0mm column was maintained at 40◦C through-out the elution series. Detection was 
achieved via PDA and MS.    
 
 
NMR Analysis 
 
  All NMR samples were solvated in 600 uL of CDCl3. 1H spectra were acquired 
via a Spectrospin automated 400 MHz Bruker spectrometer, while 2D data were acquired 
on a Varian Inova spectrometer operating at 600 MHz. 
 
Flash Chromatographic Separation of Crude Lipid  
 
 Crude lipid extracts were solubilized in 1:1 CHCl3:CH3OH through the aid of 
sonication. 1 g of dry chromatographic silica was added to the lipid solution and brought 
to dryness via rotovap. The lipid loaded silica was transferred to a previously equilibrated 
12 g Biotage HP-Sil SNAP flash chromatographic cartridge. Elution was achieved via a 
gradient separation from CHCl3 to 3:1 CHCl3: CH3OH over 15 column volumes at a flow 
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rate of 12 mL/min.  Detection was achieved via UV absorbance at 220 and 254 nm. All 
fractions were collected in glass tubes and were brought to dryness via turbovap.  
 
Mycolactone Methods 
 
 
Isolation of Mycolactone from Ulcerans  
 
M. ulcerans was grown in solid 7H11 plates for 14-16 weeks. Colonies were 
manually selected and transferred into a PBS solution where they were harvested by 
centrifugation and again washed with PBS. All PBS was then removed and 5x 
weight/volume of 5:1 EtOH:H2O was added and extracted for one hour at 37◦C. The 
solution was then clarified via centrifugation and the supernatant decanted.  The 
extraction process was repeated until the EtOH solution no longer retained a yellow 
coloration (2-3x). The extracts were brought to dryness via rotovap. The dry materials 
were resolvated in acetone with the aid of sonication and filtered to remove remaining 
cellular debris then again brought to dryness via rotovap  
 
 
Sunlight Induced Photodetoxification of Mycolactone  
 
  1 mL of mycolactone solution (500 µL/mL) was applied to transparent plastic 
plates. The plates were slowly rotated to allow the formation of a thin film and randomly 
assigned to two groups. The control group was carefully wrapped in parafilm then 
aluminum foil. The exposure group was covered with a transparent quartz slides, both 
sets of samples were carefully transported outdoors on a sunny day near 1 PM and 
exposed to sunlight for periods of 30 minutes to 2 hours. The films were then removed 
via CH3OH and analyzed via GC/MS. 
 
 
HPLC Fractionation and Analysis 
 
 All samples were dissolved CH3OH. Separations were achieved on a Phenomenex 
Luna 5µ C18(2) (250mm x 10mm x 5µm) at room temperature, flowing 3.5 mL/min of 
H20 + 0.1% Formic acid (A) and ACN+ 0.1% Formic Acid (B).  The first 12.5 minutes 
were maintained at 10% organic followed by a linear ramp to 95% organic over 45 
minutes then held at high organic for an additional 12.5 minutes resulting in a 1 hour total 
chromatographic elution. All fractions were collected in glass tubes then were turbovaped 
to dryness. The samples flagged through UV and ELSD were reanalyzed via UPLC/MS.  
Fractions found to contain mycolactone were selected for archival. 
 
 
Flash Chromatographic Separation of Crude Lipid  
 
 Crude lipid extracts were solubilized in 1:1 CHCl3: CH3OH through the aid of 
sonication. 1 g of dry chromatographic silica was added to the lipid solution and brought 
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to dryness via rotovap. The lipid loaded silica was transferred to a previously equilibrated 
12 g Biotage HP-Sil SNAP flash chromatographic cartridge. Elution was achieved via a 
gradient separation from CHCl3 to 3:1 CHCl3: CH3OH over 15 column volumes at a flow 
rate of 12 mL/min.  Detection was achieved via UV absorbance at 320 and 360 nm. All 
fractions were collected in glass tubes and were brought to dryness via turbovap.  
 
LC/MS Analysis  
  
 LC/MS Analyses were performed on both a Waters Acquity UPLC-TQD and a 
Waters Acquity UPLC-qTOF. All dry analytes were solvated in CH3OH and filtered prior 
to analysis; liquid analytes were diluted in the same and filtered. Separations were 
achieved at 0.5 mL/min via a 5 minute gradient elution from 95% H2O + 0.1% Formic 
Acid to 95% ACN + 0.1% Formic Acid as follows.  The first 30 seconds were held at the 
starting conditions then ramped to 40% organic over two minutes followed by a ramp to 
95% organic an additional two minutes then followed by a 30 second stop at the 95% 
organic before returning to re-equilibrate. A Waters Acquity C18 BEH 1.7µ x 50 x 
3.0mm column was maintained at 40◦C through-out the elution series. Detection was 
achieved via PDA and MS.    
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CHAPTER 3.    HRMS BASED METABOLIC PROFILING OF COMPOUNDS 
FOR THE TREATMENT OF TUBERCULOSIS 
 
 
Introduction to Drug Resistance 
 
Drug resistance is a general term used to indicate a chemotherapeutic agents loss 
of efficacy for a particular indication. Bacterial resistance occurs when a bacterial 
pathogen is able to survive exposure to a chemotherapeutic agent to which it previously 
was susceptible. Numerous bacterial resistance mechanisms are known to exist arising 
from mutation, natural selection and external evolutionary stresses115 (i.e., exposure to 
antimicrobial agents). It is well documented that natural product based antimicrobial 
agents as well as the bacterial genes now known to confer resistance have existed since 
antiquity.116 Unfortunately, the rampant overuse of antibiotics in both human and 
domesticated livestock populations as seen over the last half century has led to a new and 
disturbing phenomenon of greatly increased incidences of drug resistant pathogens in the 
clinic.117   
 
This overwhelming increase in the drug related selective pressures placed upon 
pathogenic bacteria has led to the development of highly virulent bacterium, resistant to 
many of the most common anti-infective compounds on which modern human society 
has come to depend.118 Numerous efforts to decrease the antimicrobial burden on animal 
food-stocks are currently underway, while most prescribers have voluntarily enlisted in 
antibiotic stewardship programs.119 While there is a near universal consensus the efforts 
to limit the selective pressures placed upon bacteria are both timely and necessary. The 
majority of the front-line antibiotics currently in clinical use have continued to see 
dramatic reductions in efficacy120 and there is a major concern that antibiotic stewardship 
efforts are being undermined by poor drug administration practices in developing 
nations.121 
 
It is becoming increasingly clear that antibiotic stewardship alone is not sufficient 
to curb the ever increasing rate of bacterial resistance.122 New antimicrobial 
chemotherapeutic agents are desperately needed to replace our aging antibacterial 
arsenal. Unfortunately, the 1980-1990’s witnessed a steep decline in both the monetary 
investment and productivity of many large-scale pharmaceutical companies as numerous 
anti-infective programs were shuttered in pursuit of therapies offering higher returns.123 
While this decade has witnessed something of a renewed interest in the commercial 
investigation of antibiotic small molecules, the battle currently appears to be favoring the 
pathogenic organisms over their human hosts. 
 
 
New Compounds Needed to Combat Antimicrobial Resistance 
 
 As ever increasing rates of resistance continue to limit the clinical efficacy of 
existing antimicrobial compounds, the need for new drugs becomes all the more urgent. 
As viewed through the lens of bacterial resistance another aspect of classical antibiotic 
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development becomes troubling. While many antibiotic agents exist on the market today, 
the vast majority of them exist as only minor modifications to previously approved drugs. 
This limited diversity in the anti-infective drug space makes not only resistance but cross-
resistance a persistent threat.124 Over 70% of the antibiotic agents approved by the FDA 
since 1982 have been modifications of only two chemotherapeutic classes, quinolones 
and beta-lactams.125 Furthermore, the golden age of antibiotic research (1940-1970) 
witnessed only 14 classes of novel antimicrobial scaffolds approved for use in humans.126 
Only five truly novel scaffolds have been approved since; mupirocin, pleuromutilins, 
lipopeptides, oxazolidinones and glycylcyclins. The question now is how does a scientist 
go about discovering a previously unknown chemical scaffold which may be 
synthetically manipulated into a chemotherapeutic agent?  
  
 The answer is both complex and multifaceted; some have chosen to screen large 
bio-diverse libraries, others have relied on structure-based design while still others have 
chosen to utilize combinatorial approaches.127 At this time there appears to be no truly 
right or wrong answer. One critical deficiency in many of the current antimicrobial drug 
development pipelines is the early preclinical investigation of an agent’s bacterial 
metabolic stability. Preclinical MS/MS screening provides scientists the ability to 
preselect drug candidates exhibiting excellent metabolic stability in the host and with 
respect to degrading enzymes found in some bacteria. Work in this chapter seeks to 
utilize high resolution mass spectrometry as a tool to investigate how both bacteria and 
the human body modify and eventually eliminate therapeutic agents modeled upon both 
spectinomycin and nitrofurantoin, and seeks to apply this knowledge towards the 
eventual synthesis of novel synthetic scaffolds. 
 
 
Introduction to Antitubercular Chemotherapeutic Agents 
 
 A number of commercially available antibiotics are currently utilized in the 
treatment of tuberculosis worldwide. Antitubercular drugs are commonly subdivided into 
first-line and second-line agents, with the first-line agents generally conferring fewer off-
target (side) effects.128 The first-line class is composed of rifampin, isoniazid, 
pyrazinamide, ethambutol and streptomycin.129 The second-line agents generally include 
kanamycin, cycloserine, ethionamide, capreomycin and para-aminosalicyclic acid.130 
While individual therapies of first and second-line agents may be capable of inhibiting 
the proliferation of tuberculosis, TB mono-therapies have been largely discontinued due 
to the rapid conference of drug resistance.131 The current CDC recommendation for TB 
infection is RIPE132 (rifampin, isoniazid, pyrazinamide, ethambutol) coadministration for 
two months followed by an additional 4-6 months of rifampicin and isoniazid. In cases of 
suspected multidrug resistant tuberculosis (MDR-Tb) RIPE therapy is recommended for 
18-24 months.133 While RIPE therapy confers a near 95% cure rate when administered as 
directed, the complicated dosage form (up to 20 pills daily) often results in poor patient 
compliance and subsequent manifestation of MDR-TB.134 New TB drugs are desperately 
needed both to replace chemotherapies relegated through resistance as well as to offer 
increased patient compliance through reduced dosage frequency. Encouragingly there are 
a number of new TB chemotherapies currently in clinical trials, including; LL-3858, PA-
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824, OPC-67683 and KRM-1648(Rifalzil), which soon may afford adjunctive 
administration to RIPE, potentially reducing the duration of RIPE therapy and associated 
patient non-compliance.     
 
 
Introduction to M. tuberculosis Pathogenicity  
 
The wide spread use of antitubercular agents coupled with poor patient 
compliance and HIV co-infection has led to a drastic increase in the instance of drug 
resistant infections seen in the clinic over the past twenty years.135 While numerous “best 
practice” strategies seek to limit the evolutionary pressure collectively placed upon 
pathogenic bacteria such as tuberculosis, new antitubercular compounds will be required 
to effectively combat infections in the near future.136 The key to the development of any 
new antibacterial agent is an advanced understanding of the mammalian immune system 
and of the strategies tuberculosis employs to evade it. The human immune system and 
infectious tuberculosis bacteria have co-evolved together, with each organism seeking to 
develop more effective countermeasures against the other. On the front line of this ever-
present conflict are the phagocytes seeking to envelop and destroy evading 
microorganisms and obligate human pathogens such as M. tuberculosis which seek to 
corrupt these biochemical machines for their own gain.137 
  
Phagocytes are white blood cells tasked with internalizing and destroying 
invading organisms and are often loosely grouped based upon their affinity for 
phagocytosis. The most aggressive or professional phagocytes (macrophages, monocytes, 
neutrophils dendritic and mast cells) are specially equipped to ingest and destroy large 
cells including bacteria.138 Phagocytes are capable of detecting pathogens both indirectly 
through opsonins (commonly IgG) and directly through the use specific receptors pre-
sensitized to antigens expressed upon bacterial cell walls. Once an invading bacterium 
has trigger the phagocyte, a phagosome is formed through the remodeling of actin aided 
by phosphoinositides and myosin X.139    
 
The ultimate goal of this remodeling is to move the bacterium from a free 
environment to a completely encapsulated compartment of the phagocyte in a process 
known as phagosome sealing. Once the phagosome is complete the process of maturation 
may begin, in the maturation stage a number of lysosomes are fused with the newly 
formed phagosome and the lumen is slowly acidified.140  
 
As the early phagosomal lumen continues to acidify, additional biochemical 
processes are responsible for beginning to confer antibacterial properties to the phagocyte 
through the activation of numerous GTPases and SNARE proteins. Once the pH falls 
below about 6.0, proton-pumping V-ATPases are recruited to further drive the luminal 
acidification in this so called late phagosome.141 The late phagosome continues to be 
enriched through the incorporation of proteases and liposomal proteins, ultimately 
resulting in the creation of phagolysosome. An organelle specifically created for its 
devastating antimicrobial properties. Phagolysosomes, rely on a number of powerful 
weapons to completely destroy the encapsulated microorganism; the foremost being a 
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highly acidic phagosome (pH 4.0 - 5.0) as well as antimicrobial peptides, proteases, iron 
scavengers (such as lactoferrin) and NADPH family oxidases.142   
 
While the immune system has evolved powerful defenses against most bacteria, 
some bacterial pathogens, including M. tuberculosis, have developed advanced strategies 
seeking to subvert or attenuate a normal immune response. Though numerous microbial 
organisms have devised systems to elude the immune system, there exist a small number 
of “professional” pathogens capable of not only surviving inside of the phagosome but 
thriving there.  
 
Mtb is one of the few successful intracellular bacterial pathogens with the ability 
to avoid many of the destructive mechanisms of the phagocytic compartment, primarily 
by preventing the phagosome from fully maturing. While the pH of the native 
phagolysosome often reaches 4.5, the phagosomal acidification of Mtb infected cells 
stalls well before they reach toxic levels143 (pH 6.4). While there exists some debate as to 
how the bacterium is able to effect maturation, a number of cell wall glycolipids seem to 
have been decisively implicated in the process.144 In concert with Mtb’s ability deceive 
the phagosome, the bacterium is also able to enter a number of replicative states to further 
its ability to survive in a potentially hostile environment. Once the bacterium has 
successfully evaded the body’s initial defensive efforts it begins to proliferate rapidly. 
This period of rapid proliferation, primarily concentrated to the alveolar macrophages, 
continues until the host is able to mount an acquired immune response.145   
 
At this point in the infection the bacterial count begins to plateau, many of the 
initial overt signs of the disease fade and the pathogen enters a stage of immune mediated 
control.146 While the exact cause of Mtb’s perceived stasis remains unknown, many 
believe hypoxia remains primarily responsible for control of bacterial growth in the 
chronic stages of persistent infection.147   
 
The immunological responses mounted against the invasion of M. tuberculosis 
and the pathways the pathogen employs to subvert them are complex. Mtb has evolved 
the ability to evade the early immune defenses targeted against it, as well as to package 
itself into a defensive granuloma once the body is capable of mounting a significant 
response.148 These traits have enabled Mtb to become a persistent pathogen without the 
reliance upon an animal reservoir, and have greatly complicated the treatment of 
persistent infection. However, it is hoped that a greater understanding of the human 
immune system and the mechanisms Mtb uses to usurp it will prove instrumental in the 
development of new chemotherapeutic agents against this enduring threat. To this end, 
this work seeks to provide a greater understanding of the host/pathogen symbiosis in two 
important ways. First, through the application of HRMS tools to investigate the small 
molecule bacterial metabolites (lipids and mycolactone) responsible for perturbing the 
innate immune response and secondly, to probe the chemical processes that serve to 
influence the metabolism of anti-infective chemotherapies. 
  
 62 
An Overview of MS Metabolic Profiling 
 
The initial discovery and subsequent testing of any new therapeutic agent is an 
extremely expensive and time-consuming venture. Current estimates place the cost of 
deploying a novel therapeutic compound at around one billion dollars with an average 
time to market of just over twelve years.149 To remain competitive, any serious venture 
must have some framework on which to evaluate the many hundreds if not thousands of 
hits often generated by modern cell based screening of large chemical libraries. Add to 
this cost the troubling high rate of attrition, over 70% off all new chemical entities 
(NCEs) ultimately fail and the potential impact to both the pharmaceutical industry and 
academic researcher is severe.150 Beyond these initial expenses, one must also consider 
the potential implications to the patient, as adverse drug reactions (ADR) due to 
unfavorable drug metabolism and pharmacokinetics (DMPK) is a leading cause of NCE 
withdrawal. 
 
From this flood of data researchers must ultimately select a small number of lead 
compounds to undergo a battery of costly test aimed at evaluating a potential NCE’s 
efficacy as well as its’ toxicological profile. A number of relatively new analytical 
techniques have proven themselves indispensable in their ability to rapidly evaluate 
NCEs throughout the development and testing process. Nobilis states,151 high throughput 
liquid chromatography tandem mass spectrometric (LC-MS/MS) techniques coupled with 
medium throughput, high information content, liquid chromatography nuclear magnetic 
resonance spectroscopy (LC-NMR) have proven invaluable in their ability to quickly 
evaluate NCEs. LC-MSn techniques have proven applications throughout the evaluation 
of chemical leads. From early hit identification and sample quantification, through 
traditional adsorption-distribution-metabolism-excretion (ADME) workflows and finally 
onto the prediction of ADRs through the investigation of potentially reactive chemical 
species152 (RCSs).    
 
This work will primarily focus on the application of LC-MSn techniques to the 
identification of metabolites as RCSs and the pharmacokinetic (PK) profiling of drug 
metabolism. Over countless years the human body has evolved defenses against the 
incursion of foreign or exogenous compounds, these xenobiotic agents are systematically 
functionalized through a series of chemical reactions leading to the increase of a toxins 
hydrophilicity and ultimately to its excretion.153 These biochemical reactions may be 
further subdivide into two metabolic phases; phase I, cytochrome P450 mediated 
biotransformations often seeking to insert a nucleophile (commonly hydroxyl) decreasing 
a compound’s lipophobicity and inserting a site for the ultimate phase II conjugation and 
excretion of a drug through the urine.154 Given these transformations usually occur in a 
predictable manner and aided by advances in synthetic physical property prediction 
algorithms, scientists now have the ability to generate metabolic profiles of a lead 
therapeutic compound in advance of costly clinical trials. These projected PK profiles 
coupled with synthetic metrics of solubility, distribution, polar-surface-area (PSA) etc., 
may then be used in selecting chemical leads to continue through the development 
pipeline.155 
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As noted earlier, the modern PK framework must be capable of handling the 
heavy workflows endemic to drug discovery laboratories, as such, tasks must be logically 
ordered so that rapid, automated (information poor) analysis may be used to guide more 
time consuming, information rich, steps. The initial classification of most NCE 
metabolites will often be conducted with the aid of the TQD, as a number of different 
experiments may be conducted in a highly efficient fashion. One of the most common 
experiments156 involves the operation of a single quadrupole (Q1) in the TQD.  This 
single scan acquisition is used to rapidly provide data such as; ionization efficiency (the 
ability to detect positively or negatively charged molecular ions), nominal mass 
difference (mass of parent +/- mass of analyte) and qualitative nitrogen content according 
to the “nitrogen rule”.  The so called nitrogen rule states that organic compounds 
containing exclusively hydrogen, carbon, nitrogen, oxygen, silicon, phosphorus, sulfur, 
and the halogens have either 1) an odd nominal mass that indicates an odd number of 
nitrogen atoms are present or 2) an even nominal mass that indicates an even number of 
nitrogen atoms are present in the molecular ion.157 
 
This easily obtainable information is then used to target more advanced TQD 
experiments, these so called precursor-ion and product-ion scans rely on the systematic 
destruction of incoming molecular ions in the TDQ’s collisional cell to create 
characteristic fragmentation patterns.  In this way, these distinct molecular fingerprints 
may be used to identify various metabolic pathways; as in the neutral loss of 176 m/z (the 
fingerprint of glucuronidation) or the precursor loss of 80 m/z (indicative of sulfation).  
The data generated from scanning and collision induced analysis may then be used in the 
design of multiple reaction monitoring (MRM) assays, in which the fragmentation 
patterns of known metabolites are preselected, effectively eliminating background 
noise158. In this way MRM experiments can prove to be extremely valuable in the 
quantification of metabolic products, while a truly powerful technique, MRM 
experiments usually reside at the end of the TQD based workflow as the design of a 
meaningful MRM experiment can prove very time consuming. See Table of 
Characteristic Metabolic Transformations (Appendix A and Tables 3 and 4). 
 
While the TQD remains the workhorse of most any metabolomics laboratory, 
recent advances in bench-top high resolution mass spectrometers (HRMS) have allowed 
many institutions access to the world of accurate mass spectrometry.159 HRMS data has 
proven extremely valuable for the predication of proposed chemical formula based upon 
a compounds isotopic elemental abundance or mass defect. Trace level metabolic 
pathways can now be rapidly elucidated based upon the mass defect observed between 
parent and metabolized products aided by the complimentary fragment data provided by 
TQD analysis. 
 
HRMS Stability Analysis of Spectinomycin Derivatives  
 
Our laboratory has an ongoing effort to synthesis new spectinomycin analogs in 
an effort to overcome the primarily, efflux pump mediated, resistance that precludes the 
parent compound from widespread clinical compatibility. Three of the lead compounds in 
our spectinomycin derivative series are Lee-1329 (Figure 33), Lee-1544 (Figure 34) and  
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Figure 33. Structure of Lee-1329 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Structure of Lee-1544 
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Lee-1599 (Figure 35). The identification of these metabolites was sought to guide further 
medicinal chemistry efforts and evaluate potential metabolite related toxicities and to 
study the potential for drug interactions. Using a careful structural analysis of these drugs 
a number of theoretical metabolic sites and products were proposed as illustrated for Lee-
1329 (Figure 36) and Lee-1544 (Figure 37). Based upon the initial findings HRMS 
experiments were designed to determine the exact nature of metabolic products both in-
vivo and in-vitro. Initial microsomal stability studies indicated Lee-1329 and Lee-1544 
were susceptible limited metabolic degradation. Preliminary rat liver microsomal phase-II 
metabolism stability data indicated Lee 1329, 1544 and 1599 did not serve as substrates 
for glucuronide conjugation nor were they significantly degraded through sulfo-
conjugation. However, primary screens indicated Lee 1544 was significantly metabolized 
phase-II glutathione conjugation.160,161 
 
 
MassLynx and HRMS Analysis of Microsomal Stability  
 
 Preliminary data indicated both 1329 and 1544 were poor substrates for 
elimination via glucuronidation (Figure 38) or sulfo-conjugation (Figure 39) and these 
results were confirmed upon HRMS Analysis. The further investigation of GSH 
conjugation products was, however, more involved (Figure 40). The more nonpolar 1544 
will be utilized to illustrate the applications of HRMS metabolic profiling. The first minor 
departure from the initial finding is that a global comparison of the parent drug across all 
microsomal samples indicated that while the concentration of parent drug was reduced in 
the GSH plates, 1544 was more stable than initially expected. Upon data analysis an 
extracted ion integration of the parent 1544 (487.2 m/z) revealed that 91-93% of the 
parent 1544 remained unchanged depending on the particular extract analyzed.  
 
Upon background subtraction and analysis the GSH analytes were found to 
contain two interesting highly polar compounds apparently related to the parent 1544 
(487.2165 m/z, 1.43 min). The GSH compounds contained two interesting co-eluting 
peaks at 0.51 (308.1049 m/z) and 0.63 (613.2486 m/z) minutes, respectively (Figures 41 
and 42).   
 
As numerous pathways exist to further detoxify GSH conjugation products the 
lack of the prototypical Δ 306 m/z has been previously reported, especially in hydrophilic 
halogenated substrates.162 Figure 43 illustrates a free GSH moiety while Figure 44 is 
the observed GSH-1544 Conjugation Product.  
 
 
MassLynx and HRMS Urinalysis of Lee Compounds  
 
Upon completion of the in-vivo studies, the program was advanced in an effort to 
elucidate the metabolic fate of 1544 in rats. Sprague Dawley rats were catheterized and 
dosed the investigational spectinomides intravenously at 10 mg/kg body weight.  The 
urine was collected on six hour intervals for the first 12 hours, then on 12 hour intervals 
for an additional 60 hours. The crude urine was processed via centrifugation and CH3OH   
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Figure 35. Structure of Lee-1599 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Possible Metabolites of Lee-1329 
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Figure 37. Possible Metabolites of Lee-1544 
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Figure 38. Preliminary Phase 2 Glucuronide Conjugation of Lee Compounds 
and Control in Rat Liver S9 Microsomes 
 
NOTE:  All Lee compounds appear highly stable.  
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Figure 39. Preliminary Phase 2 Sulfo-Conjugation of Lee Compounds and 
Control in Rat Liver S9 Microsomes  
 
NOTE:  All Lee compounds appear highly stable.  
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Figure 40. Preliminary Phase 2 Glutathione Conjugation of Lee Compounds and 
Control in Rat Liver S9 Microsomes  
 
NOTE:  Lee compounds 1329 and 1599 appear highly stable, while Lee 1544 suffered 
some metabolism. 
 
  
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0 50 100 150
%
 re
m
ai
ni
ng
 o
f P
ar
en
t 
Time in minutes 
% remaining of parent compound after Glutathione 
conugation in Rat Liver S9 
Lee 1329
Lee 1544
Lee 1599
Acetaminophen
 71 
 
 
Figure 41. Extracted Ion Spectra of Lee 1544 Remains Unchanged at the 
Conclusion of Microsomal Incubation, Indicating 1544 Is Significantly More Stable 
than Initially Predicted 
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Figure 42. Comparison of Microsomal HRMS Extracted TIC for Lee 1544  
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Figure 43. Structure of Protonated GSH  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Structure of Protonated 1544 GSH Conjugation Product  
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protein precipitation. Recent modifications in our methodology have allowed the 
detection of the 1544 parent out to the 60 hour timepoint. (Figure 45). 
 
 
HRMS Stability Analysis Conclusions and Discussion  
 
We have been able to identify free glutathione as well as a previously unknown 
1544 GSH-conjugation product aided by the high sensitivity of the qTOF. Recent 
enhancements to chromatographic methodology have enabled us to track the 1544 parent 
in rat urine over two days after a single dose of investigational compound is 
administered. The sensitivity of the HRMS has not only enabled the discovery of new 
metabolites but has provided the ability to detect extremely small concentrations of 
analyte in complex matrices. In spite of this, I was unable to detect the 1544 GSH 
conjugation product identified from in-vitro analysis in the in-vivo studies. However, I do 
not believe this to be a fault of the analytical technique, as GSH conjugation products are 
known to be rapidly degraded in rodent surrogates.   
 
 Unfortunately, the instruments high sensitivity comes at a relatively high cost. In 
sensitivity mode the accurate mass information is simply not ‘accurate’ enough for 
effective mass defect tracking or the prediction of isotopic chemical formula. The 
relatively low single dose of drug complex with the incredibly complex background of 
urine in many ways limit the application of advanced MS techniques in the same way as 
the highly polar molecules limit the application of conventional chromatographic tools. 
 
 For this reason many leading PK laboratories employ a new generation of TQD-
MS instrumentation for the investigation of phase-II metabolic conjugation through 
neutral loss and precursor scanning, unfortunately the TQD we have available in our 
department simply does not have the sensitivity or dynamic range to facilitate such 
experimentation.  
 
 In this section I wish to discuss the general lessons learned from my graduate 
work which have largely focused around the use of mass spectroscopy to study drug 
metabolites and bacterial natural products. In generating this thesis I have been advised a 
dissertation is meant to contain a succinct work and does not have to contain everything 
you have accomplished in graduate school. While at St. Jude I have generated countless 
HRMS metabolic profiles for investigational (PD30, Nitazol, FL1) new agents and 
marketed drugs alike. Cetrorelix, a new compound, has been included in this work 
(Appendix C) to demonstrate the principles of PK profiling.. While I believe our HRMS 
PK techniques have seen considerable successes, in many ways our PK workflow is 
restricted by the lack of a high sensitivity TQD. As previously mentioned most PK 
laboratories now utilize the improved dynamic range and sensitivity of modern TDQ’s to 
perform precursor and neutral loss scanning experiments for the characterization of low 
level metabolites. Unfortunately our current TQD simply does not have the sensitivity or 
dynamic range to facilitate the investigation of very dilute analytes. I believe our 
laboratories’ efforts would receive great benefit through the acquisition of a more 
appropriate TQD-MS instrumentation.  
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Figure 45. 1544 Urinalysis TIC and Extract Ion Spectra  
 
NOTE:  The parent 1544 can be easily traced past the sixty hour time point 
demonstrating the sensitivity of the HRMS technique.  
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 A number of instrument manufactures currently offer TQD-MS systems designed 
for the quantification of extremely dilute analytes. I believe the most appropriate 
instrument for the analysis of both dilute pharmacokinetic samples as well as complex 
bacterial natural products lies in an AB SCIEX 6500. This modern TQD would afford a 
near 20 fold increase in dynamic range and sensitivity compared to our current Waters 
TQD. Additionally, the 6500 is the first triple quadrupole to offer both ion mobility drive 
(SelexION) and a pulsed ion source in a single instrument. The application of ion 
mobility technology enables the interrogation of extremely complex samples (Ft lipid) 
while the pulsed ion source serves to significantly reduce background noise and further 
increase sensitivity. 
 
 Using a new generation of powerful mass spectrometers the field of preclinical 
pharmacokinetics (ADME) has witnessed intense growth over the past ten years,163 with 
our hospital (SJCRH) recently forming a preclinical PK core for the optimization of 
internally synthesized chemotherapeutic agents. I believe the continued application of 
mass spectrometric techniques in this area will continue to offer a number of benefits 
both scientifically and financially.  
 
To the scientist, early ADME data offer an opportunity to rapidly evaluate a 
potential therapeutic agent’s metabolic stability, biological distribution and route of 
elimination as well as simple metrics such as plasma protein binding and solubility. The 
availability of this type of information at the laboratory or department level allows the 
individual chemist to rapidly evaluate synthetic molecule and propose new chemical 
iterations in a rapid succession. This information also serves to provide insights into the 
potential chemical reactivity of prostatic groups and the production of highly reactive 
intermediates (toxicity). While independently these types of analysis are in no way new, 
the ability to rapidly evaluate synthetic chemotherapies in-house potentially allows each 
scaffold enumeration to occur in a matter of weeks as opposed to the months or years 
required through more traditional lot based synthetic and analytical models.  
 
From a financial standpoint, the in laboratory analysis of preclinical ADME allow 
unfavorable compounds to be excluded from the development pipeline much more 
rapidly than through traditional techniques. This pipeline annotation allows the scientist 
to evaluate the ADME implications of a particular scaffold or prosthetic modification 
prior to selecting the candidates for further enumeration This ability to further develop 
only the “most fit” compounds from a particular series not only yields dividends but 
helps to prohibit the submission of unfit compounds to the extremely costly and failure 
prone (previously outlined) NCE evaluation workflow.   
 
 
Introduction to Antitubercular Nitrofurans 
 
 It is currently held RIPE TB therapy must be maintained for very long durations 
to effectively combat latent and/or slow-growing populations of bacteria.164 These 
subpopulations of Tb infection are believed to be innately resistant to current front-line 
antibiotics due to a reduction in bacterial metabolism.165 Furthermore, these latent 
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populations often manifest as granulomas, further encapsulating the bacterium in an 
acidic, hypoxic (microaerophilic) environment,166 an environment in which nitroaromatic 
antibiotics ,including clinical candidate PA824, are thought to be one of the few classes 
of drug able to act. Our laboratories have been developing an analogous series of 
nitrofuran isoxazolines designed to effectively target latent tuberculosis, which has also 
exhibited significant efficacy against oxygen starved (NRPII) tuberculosis in-vivo.167 
Through the specific targeting of these metabolically hindered TB subpopulations new 
agents may soon be administered as an adjunct therapy to RIPE, thereby reducing the 
duration of TB chemotherapy and the potential for patient non-compliance. 
 
 
An Overview of Activity Based Profiling (Click) 
 
While the principals of activity tagging via cycloaddition of an analytical probe 
have been well established for the investigation and elucidation of large molecules; our 
laboratory sought to apply a derivative of the Cravatt technique to the investigation of 
small molecule metabolites in those of nitrofuran antibiotics. The following will briefly 
discuss the Cravatt Click methodology as applied to the investigation of a large molecule 
(serine hydrolase) for the purpose of introducing the highly validated workflows we now 
employ for the investigation of bacterial metabolites. It should also be noted the biotin-
streptavatin analytical techniques first developed in concert with Jessani served as the 
foundation for the analytical processes utilized in the investigation of our “heavy” 
metabolic products.  
 
Historically, proteomic techniques have sought to accurately measure the 
abundance of a target protein, and unfortunately, have only been able to provide an 
indirect metric of a proteins absolute activity. Similarly, many genomic tools have also 
been based upon the assumption that the abundance and activity of an enzyme remains 
directly proportional over time. Many believe this key linearity assumption 
fundamentally limits the ultimate utility of conventional proteomic and genomic tools.168  
In an attempt to overcome these limitations, Cravatt et al., sought to combine both 
chemical and biological tools into a multidisciplinary, Activity Based Protein Profiling 
(ABPP) approach “that utilizes active site-directed probes to profile the functional state 
of enzymes in whole proteomes.”169  
 
ABPP relies on the use of a synthetically derived chemical probe which interacts 
to label the active enzyme but disregards inactive or chemically inhibited isoforms, 
thereby directly reporting only the active fraction of a given protein complex. This metric 
of direct activity has proven greatly beneficial in the elucidation of major post 
translational processes directly responsible for the regulation of enzyme function.   
Since the introduction of this new approach a number of highly specific chemical probes 
have been synthesized for use in a highly diverse set of clinically relevant targets.170   
 
In 2005, Jessani and Cravatt, reported the successful application of ABPP in the 
identification of enzymes upregulated in invasive human cancer cell lines of differing 
tumor types, including urokinase (previously recognized in tumorigenesis) and the novel, 
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integral membrane serine hydrolase, KIAA1363.171 The experiment consisted of 
essentially two parts; the first involved the introduction of biotinylated-rhodamine-
fluorophphosphonate (FP) tags to prefractionated samples of human cancer cell line 
proteomes. The fractions were allowed to react at room temperature for one hour, and 
then treated with PNGaseF to deglycosylate the proteomes, reactions were quenched, run 
on SDS/PAGE and visualized via a fluorescence scanner. Absolute band intensities were 
calculated and integrated for the labeled proteins, enzyme activities were then tabulated 
by comparing multiple independently labeled reactions, data points were then averaged to 
report enzyme activities across each particular cell line.172     
 
Secondly, following gel-based separation; the labeled analytes were isolated using 
standard biotin-streptavatin based solid phase affinity purification techniques.  The 
enriched FP-labeled proteins were again separated via SDS/PAGE, with the resultant 
bands mechanically harvested and subjected to trypsin digestion. The peptidic fragments 
were then fixed using 2,5-dihydroxybenzoic acid (DHB) and analyzed using standard 
MALDI-TOF based analytical techniques, the resultant data was then cross-referenced 
against known FP-labeled and native proteins via public protein databases.173     
 
In an attempt to provide a consolidated reporting of enzyme activities profiles, the 
author conducted a cluster analysis seeking to visualize the serine hydrolase 
concentrations averaged against a cell line known to be highly active, this relativized data 
was then subjected to a hierarchical clustering algorithm with the average linkage the 
determinate of similarity. As noted earlier, the novel membrane associated serine 
hydrolase KIAA1363 was found to be consistently upregulated and has been proposed by 
the authors to represent a novel marker for cancer cell invasiveness. In addition to the 
identification of KIAA1363 the authors go on to report a number of interesting pathways 
mediated via post translational modifications, namely in cathespin A and urokinase, 
which would have been near impossible to discern without the use of ABPP 
methodology.174   
 
 
Rational for Click Metabolic Pulldown 
 
To date, a Scifinder search of “Activity Based Protein Profiling” yields over 325 
discrete hits. This volume of work conclusively illustrates the usefulness of ABPP in the 
characterization of human cancers, as well as demonstrates the potential utility of activity 
mediated cellular tagging. Following these ideas, and after careful consideration of the 
relevant literature, our lab sot to employ similar tagging and gel based separation 
techniques to investigate the method of action (MOA) and metabolic fate of nitrofuran 
based antimicrobial agents.   
 
Nitroaromatic drugs, in particular nitroimidazoles PA824 and OPC67638 are 
showing great promise as antitubercular agents in current clinical trials175. For this class 
reductive metabolic activation is known to be required for action. In 2008, Singh et al176., 
reported on nitrous oxide (NO) formation (Figure 46) and release by PA-824 (a bicyclic 
nitroimidazole) which shares a similar structure-activity relationship (SAR) to our  
 79 
N
N
O
R
N+-O
O
H+ N
N
O
R
N+O
H
H
-
O
H
N
N
O
R
N+
H
H
O
H
-O
N
N
O
R
N+-O
O
H
H
H
N
N
O
R
N-
O
H
H
O
H
N
N
O
R
N
HO
H
N
N
O
R
N
N
O
R
O
H
H
N
H2N
O
R
Reduction
+
+
Reduction
A B C
N-
OHO N
-
O H
Reduction
1 (des-nitro) 2 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Proposed Imidazole Metabolic Pathway Illustrating the Generation 
and Release of Highly Activated NO Species   
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nitrofuran analogs presumably as they reductively activated by similar pathways. 
However it is thought that the ultimate target of nitroimidazole and nitrofuran drugs is 
different, as the nitrofuran activated species is more stable and likely to form adducts.  
Coupled with the knowledge of ABPP principles, we set out to investigate the metabolic 
fate of our novel antimicrobial compounds as the nitrofuran metabolic process is as yet 
unknown in M. tuberculosis.  
 
The structure of traditional nitrofuran antimicrobial agents is illustrated for 
reference in Figure 47 (Nitrofurantoin) and representative antitubercular nitrofuran 
developed by our laboratory (Figure 48). In preliminary studies we observed that our 
nitrofurans did not release NO as observed in the Singh study with PA824 (Figure 49) 
which lead us to hypothesize that they act through radical addition rather than NO 
generation. To support this hypothesis we sought an indirect approach to study nitrofuran 
activation and targeting, in much the same way as Cravatt, has sought to supplement 
indirect proteomic click tagging techniques.    
 
Having theorized nitrofuran compounds might undergo a metabolic fate different 
to that of Singh’s nitroimidazoles, and drawing inspiration from another method often 
championed by the Cravatt lab, we designed an experiment based upon the incorporation 
of a so called “click” tag170 (Figure 50). This cycloaddition technique, popularized by 
Sharpless,177 is somewhat unique in its’ ability to couple an azide to alkyne in highly 
aqueous environments. To this end, we synthesized a number of our nitrofuran 
antimicrobial compounds to contain a solvent accessible alkyne. The probe molecules 
were designed in a way as to position the cycloaddition site away from bounds though 
necessary for protein-ligand interactions. All cycloaddition probes were tested for 
preservation of MIC, the six most active compounds were selected for continued 
investigation (Figure 51 and Table 1). We believed the incorporation of these high 
affinity tags would allow the investigation of targets of nitrofuran metabolic activation 
and ultimately mycobacterial inhibition. For simplicities sake, we termed the two 
potential targets the “light” pathway and the “heavy” pathway based on the molecular 
weight of the products. In the light fraction, small molecule conjugates and activated 
nitrofuran decomposition products were selected for via the click inclusion of a high 
activity fluorescence tag to allow detection of the product conjugates at low levels. In 
particular, one proposed conjugation was mycothiol, which is the mycobacterial analog 
of glutathione, which function is thought to as a buffer in the mycobacterial cell against 
electrophilic species. 
 
In the heavy fractions we sought to recover probe-protein conjugates, to see if 
there was a dominant proteinacous target for this inhibitor class. In both cases the small 
and biological alkyne “click” tag should allow the probes to interact with the nitrofuran 
activating enzymes and find their ultimate cellular target without blocking the binding 
state of the drugs as would be the case with larger covalently tagged probes. The click 
tags can then be conjugated to a fluorophore for the light fraction or biotin for the heavy 
fraction to allow streptavidin capture and subsequent protein analysis. From this point the 
methodology was straight forward; the probe was incubated in the presence of M. Bovis   
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Figure 47. Structure of Nitrofurantoin 
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Figure 48. Structure of Lee 1055 
 
 
 
 
 
 
 
 
 
Figure 49. Structure of PA-824 
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Figure 50. Generalized 1,3-Dipolar Azide-Alkyne Cycloaddition “Click” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Proposed Nitrofuran Metabolic Pathway Illustrating the Electron 
Cascade Ultimately Resulting in DNA Intercalation or Mycothiol Conjugation   
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Table 1. MICs of Acetylene Tagged Nitrofurans against Gram (+VE) Bacteria 
 
Click Probe  
B. 
anthracis 
sterne 
E. faecalis  
S. aureus 
ATCC29213 
(MSSA) 
S. 
pyogenes  
S. 
pneumoniae  
B. 
subtilis  
MRSA 
NRS70 
Lee 1397 >200 50 6.25 25 >200 12.5 12.5 
Lee 1521 >200 100 3.13 12.5 50 3.13 3.13 
Lee 1534 >200 200 12.5 50 100 25 6.25 
Lee 1575 >200 200 12.5 50 100 12.5 3.13 
Lee 1595 >200 200 6.25 12.5 50 6.25 6.25 
Lee 1618 >200 >200 100 >200 100 200 >200 
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(BCG) for 30 to 120 minutes, the cells were harvested and then washed to remove any 
unreacted probe. The cells were then mechanically lysed and separated into two fractions 
based  upon molecular weight through the use of centrifugal 2,000 Daltonmolecular 
weight cut-off filters. These heavy and light fractions were then reacted or “clicked” to 
one of two reporters; a fluorescent tag for the LC analysis of the light fractions (Figure 
52) or a biotinylated linker to facilitate affinity separation of the proteins contained in the 
heavy fractions. (Figure 53). 
 
The unreacted florescent azide elutes very near the conjugation product. To 
evaluate the chemical cycloaddition process a click probe (Lee-1595 is illustrated in the 
fluorescence spectra below) was allowed to react with the fluorescent azide in PBS.  The 
unreacted fluorophore elutes last (TR 17.933) slightly following the elution of the 
cycloaddition product (TR 17.525).  While the two compounds were closely eluting even 
on a longer (BPD) method, fractions were successfully collected and their identities 
conformed via MS. (Figure 54) Analytical HPLC fluorescence spectra of 1595 
conjugation products evaluating the use of MeOH (Figure 55) and ACN (Figure 56) 
organic mobile phases, MeOH was chosen due to the increases in absolute intensity, 
despite its slightly poorer chromatographic properties.  
 
Figure 57 illustrates the results of the click conjugation reaction product 
cycloaddition proceeded to near 100% completion. Figure 58 illustrates the fluorescence 
spectra from the cycloaddition reaction in BCG extract. In this spectra below,1 the parent 
(drug + fluorophore) conjugation product can be identified through the use of retention 
times (TR 6.93). A number of fluorescently tagged, presumably more polar (more early 
eluting) molecules can be seen with significant fluorescent peaks appearing at TR 6.08, 
6.38, 6.61, respectively. As these fluorescent peaks do not elute with either the unbound 
fluorophore or the fluorescently tagged drug conjugate, they must be fluorescently tagged 
molecules of an unknown nature. An effort was made to collect fractions but the short 
half-life of the potential metabolic products and dilute nature of the fractions proved to 
greatly complicate MS detection. 
 
The “light” products were then separated and analyzed via reverse phase 
fluorescence HPLC. The heavy products were “pulled down” using solid phase supported 
streptavatin beads and run out on SDS/PAGE gels. The gels were then robotically 
harvested, digested and analyzed via nanospray LC/MS, the resultant data was submitted 
for database searching. We are currently in the process of analyzing the “heavy fraction” 
search results in hopes of identifying the ultimate target of our nitrofuran based 
compounds. A number of LC runs seem to confirm the presence of low level fluorescent 
metabolites in the click tagged (light) bacterial fractions. We are now faced with the task 
of identifying these short-lived compounds; we have attempted the “semi-analytical” 
HPLC fractionation of the fluorescence peaks, then UPLC/MS of the resultant fractions.  
This offline method has not proven successful; the compounds seem to degrade between 
the purification and MS steps, while we currently do not have an UPLC/MS with a 
fluorescence detector, we are in the process of correcting this potential shortcoming. 
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Figure 52. Click Conjugation of a Light Fluorescent Probe Resulting in the 
Formation of the Fluor-Drug Cycloaddition Product  
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Figure 53. Click Conjugation of a Heavy Biotinylated Probe Resulting in the 
Formation of the Biotin-Linker-Drug Cycloaddition Product 
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Figure 54. Fluorescence Spectra of Semi-Analytical HPLC Separation of Click 
Products 
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Figure 55. Analytical HPLC Separation of 1595 Conjugation Products with 
MeOH Organic Mobile Phase 
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Figure 56. Analytical HPLC Separation of 1595 Conjugation Products with ACN 
Organic Mobile Phase 
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Figure 57. Analytical HPLC Analytical Fluorescence Spectra of 1521 
Fluorometric Conjugation Product in PBS + Catalytic TBTA  
  
 91 
 
 
 
Figure 58. Analytical HPLC Fluorescence Spectra of 1521 following BCG 
Incubation and Click Tagging 
 
NOTE: Numerous presumably metabolic products can be visualized; however, the very 
dilute analytes made further offline MS analysis impossible.   
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Our laboratory has currently synthesized six nitrofuran based “click” tags for use 
in the next iteration of this experiment. (Figures 59-64)  Overall the MIC’s of the click 
tagged compounds are quite similar to their non-derivatized parents (Table 2). 
 
 
Click Pulldown Conclusions and Discussion  
  
 The click chemistry portion of this experiment proved to be quite successful 
despite initially suffering from low yields. The addition of catalytic amounts of tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (Figure 65) was found to greatly 
increase click yields through the stabilization of the copper/azide intermediate.178 The 
probes also retained reasonable antimicrobial activity upon addition of the acetylene tag.  
The shortcoming lied in that when our laboratory initially conducted these experiments 
we did not yet have access to a high sensitivity mass spectrometer. 
 
 The initial analytical workflow relied on the use of an HPLC equipped with only a 
UV/Vis and fluorescence detector. The hope was that the resultant fluorescent signals 
would be sufficient to collect small fractions of effluent using the fluorescence signal as a 
gate. While we were able to detect fluorescent components in the supernatant samples, 
we were unable to identify them any further, due to both the metabolites relatively short 
half-life and the incredible dilution factor involved in the collection of fractions. 
 
 The high mass click tagging system proved to be successful, it just failed to 
identify any novel proteins or suggest alternative modifications to previously known 
targets.  However, I still remain quite confident in the utility of this analytical technique, 
as both tagging strategies were successful on their own right. The light fractionation 
project ultimately failed due to lack of instrumentation not experimental design.  The 
high mass tagging worked; it just failed to find anything new. 
 
 In light of recent additions, to both departmental instrumentation, and due to an 
increased knowledge of the nitrofuran bacterial targets we are currently preparing to 
revisit the light click tagging procedure for the identification of both nitrofuran and other 
metabolites.    
 
While this project has perhaps been the most challenging to date, I also believe it 
holds the most future promise as a tool uniquely suited to elucidate previously unknown  
 
 
 
 
 
 
 
Figure 59. Structure of Click Probe Lee 1397  
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Figure 60. Structure of Click Probe Lee 1521 
 
 
 
 
 
 
 
 
 
 
Figure 61. Structure of Click Probe Lee 1534 
 
 
 
 
 
 
 
 
 
 
Figure 62. Structure of Click Probe Lee 1575 
 
 
 
 
 
 
 
 
 
 
Figure 63. Structure of Click Probe Lee 1595 
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Figure 64. Structure of Click Probe Lee 1618 
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Table 2. In-vitro ADME and MIC of Click Probes 
 
Structure Mtb MIC 
Solubility 
(pH 7.4) 
ug/mL  
Permeability 
(10
-6
 cm/s) 
t1/2 
(human) 
t1/2 
(mouse) 
Protein 
binding 
(human) 
Protein 
binding 
(mouse) 
 
0.2 22.6 177.9 1.65 0.34 90.4 94.6 
 
0.2 24.8 39.9 2.88 0.56 72.0 70.0 
 
<0.0001 3.4 363.3 >50 0.93 98.1 98.5 
 
0.025 5.1 96.5 23.64 0.74 91.0 82.6 
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Figure 65. Structure of TBTA 
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small molecule bacterial metabolic pathways for bioactivated drugs. We have shown a 
high yielding cycloaddition can be performed in a variety of solutions through the 
addition of catalytic amounts of TBTA. We have also been able to visualize fluorescent 
conjugations products upon incubation with BCG. Unfortunately, our limited analytical 
instrumentation coupled with the relatively unstable nature of the metabolites prevented 
the acquisition of fluorescence associated mass spectrometric values.   
 
 To address this shortcoming, I am currently in the process of coupling an ultra-
high resolution fluorescence detector (Shimadzu RF-10AXL) to our newly acquired 
UPLC-qTOF.  Through the use of this specially hyphenated instrument I am confident we 
will finally achieve fluorescence and mass spectrometric data simultaneously.  These two 
highly sensitive analytical techniques applied in concert will allow the identification and 
ultimate structural elucidation of the “light” click fragments which has eluded us to date. 
Upon significant validation, I believe these Click-HRMS techniques will serve to 
revolutionize the way not only our laboratory accesses scaffold stability, but serve to 
advance the field of antimicrobial research through the elucidation of previously 
unknown bacterial xenobiotic detoxification strategies.  
 
 The most immediate ways I would like to further this project include repeating the 
BCG nitrofuran experiment with our new instrument as well as further investigating the 
metabolism of our click probes in MRSA. In primary screening our click tagged 
nitrofuranal compounds displayed significant efficacy against MRSA (Table 3). As we 
are very near establishing a pipeline for the click pulldown and analysis of metabolic 
products it would be quite simple to “change bugs” in our experimental procedure. I 
believe these insights could prove significant in a number of ways, first as a cross 
validation of our analytical processes. Secondly, I would like to determine if nitrofuran 
metabolism differs between bacterial species? This line of analysis could also serve to 
evaluate the target of mycolactone as very little is currently known regarding the necrotic 
processes at work in Buruli ulcer. Once current handling and archival difficulties are 
addressed, as I believe they soon will be, I would like to further investigate mycolactone 
induced necrosis through the development of acetylene tagged mycolactone (Figures 66 
and 67). The processes underlying the host response and detoxification of mycolactone 
are currently unknown. 
  
 I would also like to investigate the metabolic processes involved in the bacterial 
detoxification of linezolid, an oxazolidinone antibacterial agent proven to be effective in 
the treatment of vancomycin-resistant enterococci (VRE) as well as MRSA. In many 
ways linezolid constitutes our last line of defense against clinical presentations of gram 
positive vancomycin resistant bacteria associated skin and soft tissue infections (SSTI). 
While the approval of linezolid was heralded as a significant breakthrough in the battle 
against drug resistant bacterium, numerous clinical presentations of linezolid resistant 
infections have been reported.179 From the synthetic standpoint an acetylene tagged 
linezolid should be relatively easy to synthesize. This novel, click conjugated probe 
(Figure 68) could then prove instrumental to the interrogation of the linezolid bacterial 
bioremediation process and afford new insights into the metabolic mechanisms at work in 
linezolid resistant enterococci and staphylococcus.  
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Figure 66. Structure of Proposed Mycolactone Click Probe to Enable HRMS 
Analysis of Polyketide Core 
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Figure 67. Structure of Proposed Mycolactone Click Probe to Enable HRMS 
Analysis of Acyl Side Chain 
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Figure 68. Structure of Proposed Linezolid Click Probe 
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Experimental Methods 
 
The experimental methods developed throughout this chapter are outlined below.  
 
 
HRMS Stability Analysis Methods 
 
 
Preparation of Urinalysis Samples 
 
 All urine samples were thawed at room temperature and briefly vortexed to 
homogenize. 50 µL of each urine sample were transferred to microcentrifuge tubes 
containing 200µL of CH3OH and proteins allowed to precipitate at -20◦C for 20 minutes. 
The suspensions were clarified via ultracentrifugation and 80 µL of the supernatant was 
removed for UPLC/MS analysis.  
 
 
UPLC/MS Analysis  
  
 LC/MS analyses were performed on both a Waters Acquity UPLC-TQD and a 
Waters Acquity UPLC-qTOF. All dry analytes were solvated in CH3OH and filtered prior 
to analysis; liquid analytes were diluted in the same and filtered. Separations were 
achieved at 0.5 mL/min via a 5 minute gradient elution from 95% H2O + 0.1% Formic 
Acid to 95% ACN + 0.1% Formic Acid as follows. The first 30 seconds were held at the 
starting conditions then ramped to 40% organic over two minutes followed by a ramp to 
95% organic an additional two minutes then followed by a 30 second stop at the 95% 
organic before returning to re-equilibrate.  A Waters Acquity C18 BEH 1.7µ x 50 x 
3.0mm column was maintained at 40◦C through-out the elution series. Detection was 
achieved via PDA and MS. 
 
 
Click Pull-down Methods 
 
 
Click Pulldown in BCG 
 
BCG stocks were grown in liquid agar to an OD of 0.5. Bacterial stocks were 
transferred in to culture flasks, administered click probes at 10x MIC and incubated at 
37◦C for 48 hours, then harvested via centrifugation. The pellets were twice washed in 
PBS and centrifuged. The pellets were then resuspended in 700µL of PBS for bead-
beating. The resultant solution was clarified via centrifugation and the supernatant 
decanted. The supernatant was separated in two fractions via size exclusion membrane 
(2,000 amu). All fractions were collected and stored frozen until the completion of the 
experiment. 
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All samples were thawed at room temperature and briefly vortexed to 
homogenize.  The extracts were then transferred into a microwave tube containing of 1:1 
CH3OH:H2O (2.5mL) 100uL of previously prepared (100µg/mL in CH3OH) tag was add 
to the tube with a catalytic quantity of TBTA. The samples were allowed to react stirring 
slowly in a 37◦C oil bath overnight. Upon completion the organic solvents were removed 
from the reaction mixture via rotovap under soft vacuum the aqueous solutions were 
filtered and vialed for UPLC or SDS/PAGE Analysis. 
 
 
HPLC Separation of Click Conjugation Products 
 
All samples were dissolved in GC/MS grade CH3OH and transferred to 
autosampler vials. Separations were achieved on a Grace Davidson Prevail C18 Select 
Rocket Column (53mm x 7mm x 3µm)  at 50◦C, flowing 2.5 mL/min of H2O + 0.1% 
Formic acid (A) and ACN+ 0.1% Formic Acid (B). The first 12.5 minutes were 
maintained at 10% organic followed by a linear ramp to 95% organic over 45 minutes 
then held at high organic for an additional 12.5 minutes resulting in a 1 hour total 
chromatographic elution. All fractions were collected in glass tubes then turbovaped to 
dryness. The samples flagged through UV and ELSD were reanalyzed via UPLC/MS. 
Fractions found to contain lipid moieties were divided 1:10 for bioanalysis and archival 
respectively. 
 
 
MS Identification of Heavy Fractions  
 
The protein gel bands were reduced and alkylated with iodoacetamide and 
digested with Trypsin. Mass spectrometric analysis was performed using an LTQ 
Orbitrap Mass Spectrometer from Thermo Electron (San Jose, CA). This instrument 
employs electrospray ionization (ESI), in conjunction with an Orbitrap mass analyzer. 
The digest was introduced into the instrument via on line chromatography using reverse 
phase (C18) ultra-high pressure liquid chromatography on the nanoAcquity (Waters, 
MA).   The column used was a Waters BEHC18 with an I.D. of 75um and bed length of 
10cm.  The particle size was 1.7um.  Peptides were gradient eluted into the linear ion trap 
through a non-coated spray needle with voltage applied to the liquid by increasing the 
concentration of acetonitrile. Data acquisition involved acquiring the peptide mass (MS) 
spectra followed by fragmentation of the peptide to produce MS/MS spectra that provides 
information about the peptide sequence. Database searches were performed using 
LTQ.raw files in combination with the Mascot search engine. Protein/peptide 
assignments were made on the basis of MS/MS spectra. 
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APPENDIX A.  MASS DIFFERENTIAL OF COMMON METABOLITES  
 
 
The following tables serve to illustrate the nominal mass change(s) indicative of 
common metabolic transformations both via MS180 (Table 3) and MS/MS181 (Table 4) 
scanning modes.  
 
 
Table 3. Common Metabolic Reactions and Their Associated Nominal Mass 
Differences 
 
Conjugate m/z 
Acetylation 42 
Carbon Hydroxylation 16 
Demethylation -14 
Epoxidation 16 
Glucuronidation 176 
Glutamine Conjugation 145 
Glycine Conjugation 57 
Methylation 14 
N-Hydroxylation 16 
N-Oxidation 16 
Oxidative Desulfuration -32 
Phosphorus Oxidation 16/17 
Sulfation 80 
Taurine Conjugation 107 
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Table 4. Characteristic Fragments of Drug Conjugation via MS/MS Scanning 
 
Conjugate Ionization Mode MS/MS Scan Mass 
Aliphatic Sulfates Negative Precursor 97 
Aliphatic-GSH Positive Neutral Loss 129 
Aryl-GSH Positive Neutral Loss 275 
Carnitine Butyl Esters Positive Precursor 103 
Coenzyme A Thioesters 
(-) Negative Precursor 329,358 
Coenzyme A Thioesters 
(+) Positive Precursor 428 
Glucuronides Both Neutral Loss 176 
N-Acetylcysteines Negative Neutral Loss 129 
Phenolic sulfates Positive Neutral Loss 89 
Phosphates Negative Precursor 63,79 
Sulfinates Negative Neutral Loss 64 
Sulfonates Negative Precursor 81 
Taurines Positive Precursor 126 
Taurines Negative Precursor 339,358 
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Chemical Formula: C11H22O2
Chemical Formula: C13H26O2
Chemical Formula: C11H22O3
Chemical Formula: C15H30O2
Chemical Formula: C17H34O2
Chemical Formula: C19H38O2
Chemical Formula: C19H36O2
Chemical Formula: C21H42O2
Chemical Formula: C21H40O2
Chemical Formula: C23H46O2
Chemical Formula: C23H44O2
APPENDIX B.  STRUCTURES OF FAME GC/MS PEAKS #2 - #11 
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APPENDIX C.  SUPPORTING PK INFORMATION  
 
 
 
 
Figure 69. HRMS Identification of Nitazol Metabolite 
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Figure 70. HRMS Idenification of PD30 Metabolite 
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Figure 71 Quantification of Nitazol Metabolite 
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Figure 72. Structure of Cetrorelix 
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Figure 73. HRMS Stability Study of Cetrorelix 
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Table 5.  Calculated Cetrorelix Stability 
 
Sample Lot Sample Peak Area 
5-May-11 T1 139899 
  T2 136344 
  T3 141620 
 
6-May-11 T4 142874 
  T5 141716 
  T6 139841 
 
Mean (T) 
 
140382 
 
After 7 Days  O1 71464 
  O2 71580 
  O3 69584 
 
Mean (O) 
 
70876 
 
Blank B1 59 
  B2 67 
  B3 48 
 
Mean Blank 
 
58 
  
    
  Mean Lifespan (hrs) 
 
192 
 
Mean Degradation (% avg) 
 
0.504673696 
 
Mean Lifespan (Calculated)   190.221921 
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APPENDIX A.    MASS SPECTROMETER PARAMETERS 
 
 
TQD MS1 Parameters   
 
 
Instrument Parameters - Function 1: 
Parameter File - C:\MassLynx\Jerrod_Quant.PRO\ACQUDB\JSS_Quant1.ipr 
Polarity ES+ 
CalibrationDynamic 1 
Capillary (kV) 3.00 2.98 
Cone (V) 75.00 77.41 
Extractor (V) 3.00 2.20 
RF (V) 0.10 
Source Temperature (°C) 150 148 
Desolvation Temperature (°C) 300 300 
Cone Gas Flow (L/Hr) 40 40 
Desolvation Gas Flow (L/Hr) 500 498 
Collision Gas Flow (mL/Min) 0.10 0.01 
LM 1 Resolution 9.81 
HM 1 Resolution 15.25 
Ion Energy 1 0.35 
MS Mode Entrance 50.00 
MS Mode Collision Energy 3.00 
MS Mode Exit 50.00 
MSMS Mode Entrance 50.00 
MSMS Mode Collision Energy 75.00 
MSMS Mode Exit 50.00 
LM 2 Resolution 13.74 
HM 2 Resolution 15.25 
Ion Energy 2 0.97 
Gain 1.00 
Multiplier -648.97 
Active Reservoir B 
Engineers Settings: 
MS1 Low Mass Position       519 
MS1 High Mass Position      441 
MS1 Low Mass Resolution     518 
MS1 High Mass Resolution    803 
MS1 Resolution Linearity    750 
MS1 High Mass DC Balance    -0 
MS1 DC Polarity             Positive 
MS2 Low Mass Position       520 
MS2 High Mass Position      449 
MS2 Low Mass Resolution     512 
MS2 High Mass Resolution    689 
MS2 Resolution Linearity    825 
MS2 High Mass DC Balance    -0 
MS2 DC Polarity             Positive 
HM RF Lens Correction +  0 
HM RF Lens Correction -  0 
Inter-scan delays: 
Automatic Mode 
MS 1 Delay Table: 
         R     delay 
<=   0.500     0.005 
<=   1.200     0.010 
<=   2.400     0.015 
<=   6.000     0.020 
<=  15.000     0.025 
<=  25.000     0.028 
>   25.000     0.030 
MS 2 Delay Table: 
         R     delay 
<=   2.000     0.005 
<=   4.000     0.008 
<=   7.000     0.010 
<=  10.000     0.012 
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<=  20.000     0.014 
>   20.000     0.016 
 
-- PUMP -- 
 
Waters Acquity SDS 
 Run Time: 5.00 min 
 Comment:   
 Solvent Selection A: A1  
 Solvent Selection B: B1  
 Low Pressure Limit: 0 psi 
 High Pressure Limit: 15000 psi 
 Solvent Name A: Water  
 Solvent Name B: Acetonitrile  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Seal Wash: 5.0 min 
 Chart Out 1: System Pressure  
 Chart Out 2: %B  
 System Pressure Data Channel: No  
 Flow Rate Data Channel: No  
 %A Data Channel: No  
 %B Data Channel: No  
 Primary A Pressure Data Channel: No  
 Accumulator A Pressure Data Channel: No  
 Primary B Pressure Data Channel: No  
 Accumulator B Pressure Data Channel: No  
 Degasser Pressure Data Channel: No  
 [Gradient Table] 
  Time(min) Flow Rate %A %B Curve  
 1. Initial 0.500 90.0 10.0   
 2. 0.50 0.500 90.0 10.0 6  
 3. 3.00 0.500 5.0 95.0 6  
 4. 4.50 0.500 5.0 95.0 6  
 5. 4.80 0.500 90.0 10.0 6  
 Run Events: Yes  
 
-- DETECTOR --  
 
Waters Acquity PDA 
 PDA Detector Type: UPLC LG 500 nm  
 Lamp: On  
 Sampling Rate: 20 points/sec 
 Filter Time Constant: 0.1000 sec 
 Exposure Time: Auto msec 
 Interpolate 2nd order filter (340nm) Region: No  
 Use UV Blocking Filter: No  
3D Channel... 
 Range: 190  - 400   
 Resolution: 1.2 nm 
Compensation Reference 2D Parameters... 
 Range: 310  - 410   
 Initial Switch 1: No Change  
 Initial Switch 2: No Change  
 
-- AUTOSAMPLER -- 
 
Waters Acquity AutoSampler  
 Run Time: 5.00 min 
 Comment:   
 Load Ahead: Disabled  
 Loop Option: Partial Loop With Needle Overfill  
 LoopOffline: Disable  
 Weak Wash Solvent Name:   
 Weak Wash Volume: 1000 uL 
 Strong Wash Solvent Name:   
 Strong Wash Volume: 1000 uL 
 Target Column Temperature: 40.0 C 
 Column Temperature Alarm Band: Disabled  
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 Target Sample Temperature: Off C 
 Sample Temperature Alarm Band: Disabled  
 Full Loop Overfill Factor: Automatic  
 Syringe Draw Rate: Automatic  
 Needle Placement: 8.0  
 Pre-Aspirate Air Gap: Automatic  
 Post-Aspirate Air Gap: Automatic  
 Column Temperature Data Channel: No  
 Ambient Temperature Data Channel: No  
 Sample Temperature Data Channel: No  
 Sample Organizer Temperature Data Channel: No  
 Sample Pressure Data Channel: No  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Switch 4: No Change  
 Chart Out: Sample Pressure  
 Sample Temp Alarm: Disabled  
 Column Temp Alarm: Disabled  
 Run Events: Yes  
 Needle Overfill Flush: Automatic  
 Sample Loop Size: 10.0  
Sample Run Injection Parameter 
Injection Volume (ul)   -   7.50 
Cycle time (secs):         -1.000 
Scan duration (secs):      0.15 
Interscan delay (secs):    -1.00 
Retention window (mins):   0.000 to 5.000 
Ionization mode:           ES+ 
Data type:                 Accurate Mass 
Function type:             Scan 
Mass range:                300 to 900 
Function 2 
Scans in function:         6001 
Function type:             Diode Array 
Wavelength range ( nm ) :  190 to 400 
 
TQD MS/MS Parameters 
 
Instrument Parameters - Function 1: 
Parameter File - C:\MassLynx\Jerrod_Quant.PRO\ACQUDB\JSS_Quant1.ipr 
Polarity ES+ 
CalibrationDynamic 2 
Capillary (kV) 3.00 2.98 
Cone (V) 75.00 76.43 
Extractor (V) 3.00 2.69 
RF (V) 0.10 
Source Temperature (°C) 150 148 
Desolvation Temperature (°C) 300 300 
Cone Gas Flow (L/Hr) 40 39 
Desolvation Gas Flow (L/Hr) 500 498 
Collision Gas Flow (mL/Min) 0.10 0.10 
LM 1 Resolution 9.81 
HM 1 Resolution 15.25 
Ion Energy 1 0.35 
MS Mode Entrance 50.00 
MS Mode Collision Energy 3.00 
MS Mode Exit 50.00 
MSMS Mode Entrance 50.00 
MSMS Mode Collision Energy 50.0 
MSMS Mode Exit 50.00 
LM 2 Resolution 13.74 
HM 2 Resolution 15.25 
Ion Energy 2 0.97 
Gain 1.00 
Multiplier -648.97 
Active Reservoir B 
Engineers Settings: 
MS1 Low Mass Position       519 
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MS1 High Mass Position      441 
MS1 Low Mass Resolution     518 
MS1 High Mass Resolution    803 
MS1 Resolution Linearity    750 
MS1 High Mass DC Balance    -0 
MS1 DC Polarity             Positive 
MS2 Low Mass Position       520 
MS2 High Mass Position      449 
MS2 Low Mass Resolution     512 
MS2 High Mass Resolution    689 
MS2 Resolution Linearity    825 
MS2 High Mass DC Balance    -0 
MS2 DC Polarity             Positive 
HM RF Lens Correction +  0 
HM RF Lens Correction -  0 
Inter-scan delays: 
Automatic Mode 
MS 1 Delay Table: 
         R     delay 
<=   0.500     0.005 
<=   1.200     0.010 
<=   2.400     0.015 
<=   6.000     0.020 
<=  15.000     0.025 
<=  25.000     0.028 
>   25.000     0.030 
MS 2 Delay Table: 
         R     delay 
<=   2.000     0.005 
<=   4.000     0.008 
<=   7.000     0.010 
<=  10.000     0.012 
<=  20.000     0.014 
>   20.000     0.016 
-- PUMP -- 
Waters Acquity SDS 
 Run Time: 5.00 min 
 Comment:   
 Solvent Selection A: A1  
 Solvent Selection B: B1  
 Low Pressure Limit: 0 psi 
 High Pressure Limit: 15000 psi 
 Solvent Name A: Water  
 Solvent Name B: Acetonitrile  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Seal Wash: 5.0 min 
 Chart Out 1: System Pressure  
 Chart Out 2: %B  
 System Pressure Data Channel: No  
 Flow Rate Data Channel: No  
 %A Data Channel: No  
 %B Data Channel: No  
 Primary A Pressure Data Channel: No  
 Accumulator A Pressure Data Channel: No  
 Primary B Pressure Data Channel: No  
 Accumulator B Pressure Data Channel: No  
 Degasser Pressure Data Channel: No  
 [Gradient Table] 
  Time(min) Flow Rate %A %B Curve  
 1. Initial 0.500 90.0 10.0   
 2. 0.50 0.500 90.0 10.0 6  
 3. 3.00 0.500 5.0 95.0 6  
 4. 4.50 0.500 5.0 95.0 6  
 5. 4.80 0.500 90.0 10.0 6  
 Run Events: Yes  
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-- DETECTOR --  
 
Waters Acquity PDA 
 PDA Detector Type: UPLC LG 500 nm  
 Lamp: On  
 Sampling Rate: 20 points/sec 
 Filter Time Constant: 0.1000 sec 
 Exposure Time: Auto msec 
 Interpolate 2nd order filter (340nm) Region: No  
 Use UV Blocking Filter: No  
3D Channel... 
 Range: 190  - 400   
 Resolution: 1.2 nm 
Compensation Reference 2D Parameters... 
 Range: 310  - 410   
 Initial Switch 1: No Change  
 Initial Switch 2: No Change  
 
-- AUTOSAMPLER -- 
 
Waters Acquity AutoSampler  
 Run Time: 5.00 min 
 Comment:   
 Load Ahead: Disabled  
 Loop Option: Partial Loop With Needle Overfill  
 LoopOffline: Disable  
 Weak Wash Solvent Name:   
 Weak Wash Volume: 1000 uL 
 Strong Wash Solvent Name:   
 Strong Wash Volume: 1000 uL 
 Target Column Temperature: 40.0 C 
 Column Temperature Alarm Band: Disabled  
 Target Sample Temperature: Off C 
 Sample Temperature Alarm Band: Disabled  
 Full Loop Overfill Factor: Automatic  
 Syringe Draw Rate: Automatic  
 Needle Placement: 8.0  
 Pre-Aspirate Air Gap: Automatic  
 Post-Aspirate Air Gap: Automatic  
 Column Temperature Data Channel: No  
 Ambient Temperature Data Channel: No  
 Sample Temperature Data Channel: No  
 Sample Organizer Temperature Data Channel: No  
 Sample Pressure Data Channel: No  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Switch 4: No Change  
 Chart Out: Sample Pressure  
 Sample Temp Alarm: Disabled  
 Column Temp Alarm: Disabled  
 Run Events: Yes  
 Needle Overfill Flush: Automatic  
 Sample Loop Size: 10.0  
Sample Run Injection Parameter 
Injection Volume (ul)   -   7.50 
Function 1 
Scans in function:         1659 
Cycle time (secs):         -1.000 
Scan duration (secs):      0.15 
Interscan delay (secs):    -1.00 
Retention window (mins):   0.000 to 5.000 
Ionization mode:           ES+ 
Data type:                 Accurate Mass 
Function type:             Daughters of 765.00 
Mass range:                300 to 600 
Collision Energy:          50.0 
Function 2 
Scans in function:         6001 
Function type:             Diode Array 
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Wavelength range ( nm ) :  190 to 400 
 
 
HRMS Positive Mode Parameters  
 
Function Parameters - Function 1 - TOF MS FUNCTION 
Scan Time (sec)     0.500 
Interscan Time (sec)    0.014 
Start Mass     200.0 
End Mass     900.0 
Start Time (mins)    0.00 
End Time (mins)     5.00 
Data Format     Continuum 
ADC Sample Frequency (GHz)   6.0 
ADC Pusher Frequency (µs)   60.0 
ADC Pusher Width (µs)    1.50 
Use Tune Page Cone Voltage   NO 
CV Ramp Start Voltage    15.0 
CV Ramp End Voltage    50.0 
Using Auto Transfer Collision Energy (eV) 6.000000 
Sensitivity     Normal 
Dynamic Range     Normal 
Save Collapsed Retention Time Data  No 
Use Rule File Filtering    No 
Calibration    Dynamic 2 
 
-- PUMP -- 
 
Waters Acquity SDS 
 Run Time: 5.00 min 
 Comment:   
 Solvent Selection A: A1  
 Solvent Selection B: B1  
 Low Pressure Limit: 0 psi 
 High Pressure Limit: 15000 psi 
 Solvent Name A: Water  
 Solvent Name B: Acetonitrile  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Seal Wash: 5.0 min 
 Chart Out 1: System Pressure  
 Chart Out 2: %B  
 System Pressure Data Channel: No  
 Flow Rate Data Channel: No  
 %A Data Channel: No  
 %B Data Channel: No  
 Primary A Pressure Data Channel: No  
 Accumulator A Pressure Data Channel: No  
 Primary B Pressure Data Channel: No  
 Accumulator B Pressure Data Channel: No  
 Degasser Pressure Data Channel: No  
 [Gradient Table] 
  Time(min) Flow Rate %A %B Curve  
 1. Initial 0.400 98.0 2.0   
 2. 0.50 0.400 98.0 2.0 6  
 3. 3.75 0.400 5.0 95.0 6  
 4. 4.50 0.400 5.0 95.0 6  
 5. 4.60 0.400 98.0 2.0 6  
 6. 5.00 0.400 98.0 2.0 6  
 Run Events: Yes  
 
-- DETECTOR --  
 
Waters Acquity TUV 
 Run Time: 5.00 min 
 Wavelength Mode: Dual Wavelength  
 Lamp On: On  
Channel A... 
 Comment:   
 134 
 Wavelength: 254 nm 
 Sampling Rate: 2 points/sec 
 Data Mode: Absorbance A  
 Time Constant: 1.0000 sec 
 Auto Zero On Wavelength Change: Maintain Baseline  
 Auto Zero On Inject Start: Yes  
Channel B... 
 Comment:   
 Wavelength: 220 nm 
 Sampling Rate: 2 points/sec 
 Data Mode: Absorbance B  
 Time Constant: 1.0000 sec 
 Auto Zero On Wavelength Change: Maintain Baseline  
 Auto Zero On Inject Start: Yes  
Analog 1... 
 Sensitivity: 2.000 AUFS 
 Chart Polarity: Positive (+)  
 Voltage Offset: 0 mV 
 Enable Chart Mark: Yes  
Analog 2... 
 Sensitivity: 2.000 AUFS 
 Chart Polarity: Positive (+)  
 Voltage Offset: 0 mV 
 Enable Chart Mark: Yes  
 Run Events: Yes  
 Pulse Width: 1.0 sec 
 Rect Wave Period: 0.2 sec 
 
-- AUTOSAMPLER -- 
 
Waters Acquity AutoSampler  
 Run Time: 5.00 min 
 Comment:   
 Load Ahead: Disabled  
 Loop Option: Partial Loop  
 LoopOffline: Disable  
 Weak Wash Solvent Name:   
 Weak Wash Volume: 1000 uL 
 Strong Wash Solvent Name:   
 Strong Wash Volume: 500 uL 
 Target Column Temperature: 37.0 C 
 Column Temperature Alarm Band: Disabled  
 Target Sample Temperature: Off C 
 Sample Temperature Alarm Band: Disabled  
 Full Loop Overfill Factor: Automatic  
 Syringe Draw Rate: Automatic  
 Needle Placement: Automatic  
 Pre-Aspirate Air Gap: Automatic  
 Post-Aspirate Air Gap: Automatic  
 Column Temperature Data Channel: No  
 Ambient Temperature Data Channel: No  
 Sample Temperature Data Channel: No  
 Sample Organizer Temperature Data Channel: No  
 Sample Pressure Data Channel: No  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Switch 4: No Change  
 Chart Out: Sample Pressure  
 Sample Temp Alarm: Disabled  
 Column Temp Alarm: Disabled  
 Run Events: Yes  
 Needle Overfill Flush: Automatic  
 Sample Loop Size: 10.0  
Sample Run Injection Parameter 
Injection Volume (ul)   -   5.00 
Function 1 
Scans in function:         581 
Cycle time (secs):         0.514 
Scan duration (secs):      0.50 
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Interscan delay (secs):    0.01 
Retention window (mins):   0.000 to 5.000 
Ionization mode:           ES+ 
Data type:                 Enhanced Mass 
Function type:             TOF MS 
Mass range:                200 to 900 
Function 2 
Scans in function:         601 
Function type:             Diode Array 
Wavelength range ( nm ) :  220 to 254 
 
 
HRMS Negative Mode Parameters 
 
Function Parameters - Function 1 - TOF MS FUNCTION 
Scan Time (sec)     0.500 
Interscan Time (sec)    0.014 
Start Mass     200.0 
End Mass     900.0 
Start Time (mins)    0.00 
End Time (mins)     5.00 
Data Format     Continuum 
ADC Sample Frequency (GHz)   6.0 
ADC Pusher Frequency (µs)   60.0 
ADC Pusher Width (µs)    1.50 
Use Tune Page Cone Voltage   NO 
CV Ramp Start Voltage    15.0 
CV Ramp End Voltage    50.0 
Using Auto Transfer Collision Energy (eV) 6.000000 
Sensitivity     Normal 
Dynamic Range     Normal 
Save Collapsed Retention Time Data  No 
Use Rule File Filtering    No 
Calibration    Dynamic 2 
 
-- PUMP -- 
 
Waters Acquity SDS 
 Run Time: 5.00 min 
 Comment:   
 Solvent Selection A: A1  
 Solvent Selection B: B1  
 Low Pressure Limit: 0 psi 
 High Pressure Limit: 15000 psi 
 Solvent Name A: Water  
 Solvent Name B: Acetonitrile  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Seal Wash: 5.0 min 
 Chart Out 1: System Pressure  
 Chart Out 2: %B  
 System Pressure Data Channel: No  
 Flow Rate Data Channel: No  
 %A Data Channel: No  
 %B Data Channel: No  
 Primary A Pressure Data Channel: No  
 Accumulator A Pressure Data Channel: No  
 Primary B Pressure Data Channel: No  
 Accumulator B Pressure Data Channel: No  
 Degasser Pressure Data Channel: No  
 [Gradient Table] 
  Time(min) Flow Rate %A %B Curve  
 1. Initial 0.400 98.0 2.0   
 2. 0.50 0.400 98.0 2.0 6  
 3. 3.75 0.400 5.0 95.0 6  
 4. 4.50 0.400 5.0 95.0 6  
 5. 4.60 0.400 98.0 2.0 6  
 6. 5.00 0.400 98.0 2.0 6  
 Run Events: Yes  
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-- DETECTOR --  
 
Waters Acquity TUV 
 Run Time: 5.00 min 
 Wavelength Mode: Dual Wavelength  
 Lamp On: On  
Channel A... 
 Comment:   
 Wavelength: 254 nm 
 Sampling Rate: 2 points/sec 
 Data Mode: Absorbance A  
 Time Constant: 1.0000 sec 
 Auto Zero On Wavelength Change: Maintain Baseline  
 Auto Zero On Inject Start: Yes  
Channel B... 
 Comment:   
 Wavelength: 220 nm 
 Sampling Rate: 2 points/sec 
 Data Mode: Absorbance B  
 Time Constant: 1.0000 sec 
 Auto Zero On Wavelength Change: Maintain Baseline  
 Auto Zero On Inject Start: Yes  
Analog 1... 
 Sensitivity: 2.000 AUFS 
 Chart Polarity: Positive (+)  
 Voltage Offset: 0 mV 
 Enable Chart Mark: Yes  
Analog 2... 
 Sensitivity: 2.000 AUFS 
 Chart Polarity: Positive (+)  
 Voltage Offset: 0 mV 
 Enable Chart Mark: Yes  
 Run Events: Yes  
 Pulse Width: 1.0 sec 
 Rect Wave Period: 0.2 sec 
 
-- AUTOSAMPLER -- 
 
Waters Acquity AutoSampler  
 Run Time: 5.00 min 
 Comment:   
 Load Ahead: Disabled  
 Loop Option: Partial Loop  
 LoopOffline: Disable  
 Weak Wash Solvent Name:   
 Weak Wash Volume: 1000 uL 
 Strong Wash Solvent Name:   
 Strong Wash Volume: 500 uL 
 Target Column Temperature: 37.0 C 
 Column Temperature Alarm Band: Disabled  
 Target Sample Temperature: Off C 
 Sample Temperature Alarm Band: Disabled  
 Full Loop Overfill Factor: Automatic  
 Syringe Draw Rate: Automatic  
 Needle Placement: Automatic  
 Pre-Aspirate Air Gap: Automatic  
 Post-Aspirate Air Gap: Automatic  
 Column Temperature Data Channel: No  
 Ambient Temperature Data Channel: No  
 Sample Temperature Data Channel: No  
 Sample Organizer Temperature Data Channel: No  
 Sample Pressure Data Channel: No  
 Switch 1: No Change  
 Switch 2: No Change  
 Switch 3: No Change  
 Switch 4: No Change  
 Chart Out: Sample Pressure  
 Sample Temp Alarm: Disabled  
 Column Temp Alarm: Disabled  
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 Run Events: Yes  
 Needle Overfill Flush: Automatic  
 Sample Loop Size: 10.0  
Function 1 
Scans in function:         581 
Cycle time (secs):         0.514 
Scan duration (secs):      0.50 
Interscan delay (secs):    0.01 
Retention window (mins):   0.000 to 5.000 
Ionization mode:           ES- 
Data type:                 Enhanced Mass 
Function type:             TOF MS 
Mass range:                200 to 900 
Function 2 
Scans in function:         601 
Function type:             Diode Array 
Wavelength range ( nm ) :  220 to 254 
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